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Abstract
Major depressive disorder (MDD) is the second most common mental health
condition and a leading cause of disability in the world. It is theorized that MDD
develops from a combination of biological, psychological, and social stressors. The
condition is typically treated using pharmaceuticals and psychotherapy. However, not all
individuals with MDD have access to or choose to use these treatments, or may prefer to
incorporate therapeutic lifestyle changes such as exercise, sleep, and healthy eating.
Even with treatment, MDD can alter brain structure and function, leading to the
development of comorbid mental health and chronic metabolic conditions like obesity,
cardiovascular disease, or diabetes. Physiological mechanisms that can be significantly
affected by MDD episodes include brain glucose metabolism, brain-derived neurotrophic
factor (BDNF) production and activity, and antioxidant function. This paper reviews
existing literature to examine these components of the pathophysiology of MDD and
outline how treatments could functionally improve the condition. Most research has
examined the relationship between nutrition and MDD utilizing traditional interventions,
like low-fat diets, but more recent studies have explored alternative nutrition therapies.
Animal-models have shown potential for the use of the ketogenic diet as nutrition therapy
for MDD by demonstrating improved metabolism of alternative nutrients, increased
BDNF activity, and improved antioxidant capacity in the brain. However, to date, there
are no studies that examine the effects of a ketogenic diet on a human population with
MDD. Future research is warranted to determine whether a ketogenic diet is a safe and
reliable medical nutrition therapy for MDD.
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Chapter I. Review of Literature
Introduction
MDD, also known as clinical or major depression, has a significant impact on the
personal, social, familial, and occupational function of millions of individuals in the US
and the rest of the world. According to the World Health Organization (WHO), MDD
was the fourth highest cause of disability in the world in 2013 and is on course to be the
second highest by the end of 2020.1 While the lifetime incidence of MDD has been
estimated to be between 15 to 20%, there was a 10-year prevalence rise from 6.6% in
2005 to 7.3% in 2015.1, 2 The incidence of MDD among the general population is
characterized by a variety of demographic, socioeconomic, and lifestyle factors.
Reported rates of MDD tend to be significantly higher among females,2, 3 individuals less
than 45 years old,2, 3 non-Hispanic white and Hispanic populations,2, 3 individuals with
annual incomes below $20,000,2 and individuals with at least some college education.2
Research has also revealed that MDD is two to three times more common in individuals
who already have multimorbidities compared to those with one or no chronic physical
conditions.4 This data indicates a potential risk for a cyclical or synergistic pattern of
MDD and chronic disease, due to the inflammatory effect that MDD has on human
physiology.
It has been estimated that about 56% of individuals who have depression and at
least one other chronic physical condition use antidepressants for treatment, while about
21% use psychotherapy, and about 22% report no treatment.5 With research indicating
that diet, sleep, and exercise all have a significant impact on the development,
progression, and management of MDD, there is an opportunity for creating non-
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pharmacological interventions that address these factors, especially among those
individuals not currently following any treatments for MDD.6 Additionally, the
correlation between poor mental and physical health and the prevalence of individuals
with multimorbidities warrants further research into intervention methods that can
improve multiple health conditions. To date, most research has utilized dietary
interventions that emphasize a higher intake of fruits, vegetables, and whole grains,
following a low-fat diet or exchanging high saturated fat foods for those high in
unsaturated fats or limiting the consumption of foods that are highly processed or contain
high amounts of added sugars.7 However, with the continued rise in the prevalence of
depression, it would be beneficial to continue research into the effects of nontraditional
dietary interventions that do not necessarily strictly follow to these typical eating
patterns. Therefore, this critical review will describe the pathophysiology of major
depressive disorder, including brain nutrient metabolism and oxidative stress, and the
relationship between major depression and obesity. Additionally, it will review current
research regarding the high-fat, low-carbohydrate ketogenic diet and its mechanistic
action on neurophysiological systems that are dysregulated in major depression to outline
the therapeutic potential of this type of dietary intervention in the treatment of the
condition.
Major Depressive Disorder
To better comprehend the prevalence and effects of MDD, it is necessary to
understand its status as a mental health condition and how it is categorized and diagnosed
by mental health professionals. MDD is classified as a neuropsychiatric mood disorder
and is characterized by a persistently depressed mood or loss of interest in daily
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activities. According to the Diagnostic and Statistical Manual of Mental Disorders, Fifth
Edition (DSM-V), the criteria for a diagnosis of MDD require that8:
I.

Five (or more) of the following symptoms have been present during the same 2-week
period and represent a change from previous functioning; at least one of the symptoms is
either (1) depressed mood or (2) loss of interest or pleasure.
A. Depressed mood most of the day, nearly every day, as indicated by either
subjective report (e.g., feels sad, empty, hopeless) or observation made by others
(e.g., appears tearful).
B. Markedly diminished interest or pleasure in all, or almost all, activities most of
the day, nearly every day (as indicated by either subjective account or
observation).
C. Significant weight loss when not dieting or weight gain (e.g., a change of more
than 5% of body weight in a month), or decrease or increase in appetite nearly
every day.
D. Insomnia or hypersomnia nearly every day.
E. Psychomotor agitation or retardation nearly every day (observable by others, not
merely subjective feelings of restlessness or being slowed down).
F. Fatigue or loss of energy nearly every day.
G. Feelings of worthlessness or excessive or inappropriate guilt (which may be
delusional) nearly every day (not merely self-reproach or guilt about being sick).
H. Diminished ability to think or concentrate, or indecisiveness, nearly every day
(either by subjective account or as observed by others).
I.

Recurrent thoughts of death (not just fear of dying), recurrent suicidal ideation
without a specific plan, or a suicide attempt or a specific plan for committing
suicide.

II.

The symptoms cause clinically significant distress or impairment in social, occupational,
or other important areas of functioning.
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III.

The episode is not attributable to the physiological effects of a substance or another
medical condition.

IV.

The occurrence of the major depressive episode is not better explained by schizoaffective
disorder, schizophrenia, schizophreniform disorder, delusional disorder, or other
specified and unspecified schizophrenia spectrum and other psychotic disorders.

V.

There has never been a manic episode or a hypomanic episode.

A diagnosis of MDD can include either isolated or recurrent episodes, which are typically
classified as mild, moderate, or severe. For individuals with MDD, the length and
severity of an episode can have a lasting impact on brain structure and function, while
recurrent or chronic MDD is likely to lead to the development of other chronic health
conditions.
Neuropathology.
MDD is considered to be caused by a combination of various biological,
psychological, and social stressors. These factors are likely to alter several components
of brain function, in addition to creating an inflammatory state within the body that can
affect multiple physiological organ systems. Some of these functions with which MDD
interferes in the human body include brain glucose metabolism, regulation of brainderived neurotrophic factor (BDNF), and antioxidant activity.
Glucose metabolism. Although glucose is typically the main source of energy for
the brain, there are significant alterations in the mechanisms of glucose metabolism in
populations affected by major depression. Several studies, examining individuals with
MDD and concurrent anhedonia, have demonstrated regional glucose hypometabolism
and metabolic asymmetry in the left prefrontal cortex, cerebellum, left anterior cingulate,
right insular cortex, right claustrum, right anteroventral caudate and putamen, right
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middle temporal gyrus, and right superior temporal gyrus.9-11 These alterations have also
been associated with the relative severity and course of the depressive episode, such that
individuals with severe depression are likely to have lower global cerebral glucose
metabolic rates.12 It has been shown that successful pharmacological treatment, with
specific antidepressants, can increase glucose utilization in the left prefrontal cortex;
however, whole frontal glucose metabolism was still significantly lower in both untreated
and treated MDD individuals.10 Holthoff et al. even reported decreases in regional
glucose metabolism in remitted MDD patients treated with selective serotonin reuptake
inhibitors (SSRIs) and serotonin-norepinephrine reuptake inhibitors (SNRIs).9 These
results demonstrate that specific antidepressant treatments may not induce long-term
changes in or may have absolute detrimental effects on cerebral glucose metabolism. A
possible causal link between MDD and decreased cerebral glucose metabolism was found
by Kahl et al., showing that elevated DNA methylation of GLUT1 in unremitted MDD
patients lowered GLUT1 expression in brain cells, but could be reversed through MDD
remission.13 Although the main alterations to cerebral metabolism are related to glucose
metabolic dysfunction, Mocking et al. reported another change in cerebral metabolism,
which included elevated fatty acid unsaturation and peroxidation that was negatively
associated with higher cortisol levels in individuals with MDD.14 These findings indicate
that glucose uptake from blood vessels into the brain may be compromised in untreated
and treated MDD and that another source of energy could potentially improve cerebral
metabolic rates for these individuals.
BDNF. Although brain metabolic dysfunction is an important factor in the
pathophysiology of depression, there are other noted alterations in brain function, such as

6

changes to the activity of BDNF. BDNF is the most abundant neurotrophin in the
nervous system and is involved in the development and regulation of neuronal systems,
neurotransmitter activity, and neuroplasticity.15, 16 Individuals with MDD have been
shown to have significantly lower concentrations of serum BDNF in comparison to
healthy controls.15, 17-22 Lower serum BDNF levels have also been reported during
recurrent depressive episodes as compared to first episodes,17 in individuals with longterm MDD (≥1 year) as compared to short-term MDD (<1 year),23 and in individuals with
MDD as compared to individuals with dysthymia.20 However, Sözeri-Varma et al. did
find a contrasting result by demonstrating that there was no significant difference in
serum BDNF levels between individuals in their first and recurrent MDD episodes.18 In
regard to the correlation between MDD treatment and BDNF activity, it has been
demonstrated that antidepressants can increase serum BDNF levels in individuals with
MDD.15, 19, 22 While these findings do not indicate that antidepressants only treat MDD
by improving BDNF levels, it has been suggested that low BDNF levels play an
important role in the pathophysiology of MDD and other affective disorders.15, 19, 22
Although most data appears to support this hypothesis, there is no evidence for
directionality in this relationship, and conflicting data has been shown between serum
BDNF levels and the severity of MDD and the presence of psychotic features.17, 18, 23 The
correlation between improvements to reduced BDNF levels and the severity of MDD
symptoms warrants additional research, especially regarding treatments and interventions
that can improve both of these conditions.
Oxidative Stress. Other prevalent alterations to brain function in MDD can occur
through the action of oxidative stress, which can have significant effects on brain
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structure and metabolism, and neuronal interaction. Markers of oxidative stress and
reduced antioxidant function have been repeatedly noted in individuals with MDD
compared to healthy controls.24-28 The major brain antioxidant glutathione, its
complementary enzyme glutathione peroxidase (GPx), and the detoxifying brain isozyme
glutathione S-transferase Mu 1 (GST Mu 1) were shown to be significantly lowered in
post-mortem brain tissues of individuals with MDD, bipolar disorder, and
schizophrenia24, 29 and the serum of living individuals with MDD.25, 28 There has been
one report of no difference in GPx activity between individuals with MDD and healthy
controls.26 While the previously mentioned enzymes are typically reduced during MDD,
there have also been reports of increased activity of the antioxidant enzymes glutathione
reductase,25,29 superoxide dismutase (SOD),25, 29, 30 and catalase.26, 30 However in contrast
to this, Rybka et al. did find decreased SOD activity in individuals with MDD compared
to healthy controls.28 Additionally, some of these antioxidant activities have not been
shown to improve or have even been slightly suppressed with the pharmacological
treatment of MDD.26, 29, 30 These findings illustrate that oxidative stress in psychiatric
conditions, including MDD, may be exacerbated by antioxidant dysregulation and
dysfunction. Markers of oxidative stress, such as malondialdehyde, 8-OH 2deoxyguanosine, interleukin-6, tumor necrosis factor-α (TNF-α), F2-isoprostanes,
neopterin have also been found in elevated levels in individuals with MDD, and some
have been associated with decreased effectiveness of antidepressant treatments.27-29
Interleukin-6 levels, however, were shown to be decreased by SSRI treatment.27 The
relative ineffectiveness of several antidepressant treatments for improving oxidative
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stress in MDD suggests that other therapeutic methods should be examined for the
limitation of prooxidant and enhancement of antioxidant systems.
Obesity.
Due to its similar relationship with increased oxidative stress and systemic
inflammation, it is important to discuss obesity and how it correlates with MDD. There
have been numerous large-scale, cross-sectional epidemiological and observational
studies that have examined this relationship, and have demonstrated a positive correlation
between obesity and MDD.31-35 Some studies have reported odds ratios between 1.1 and
2.09 for the risk of developing MDD when the condition is preceded by obesity.32, 36
Several studies have reported that this association occurs mainly between MDD and
severe or class III obesity (body mass index ≥ 40 kg/m2).31, 37, 38 Despite this significant
correlation, no causal direction of the MDD-obesity relationship has been officially
established. However, in their research based on the Alameda County Study, Roberts et
al. did report that obesity at baseline was associated with an increased risk of MDD five
years later, while the presence of MDD at baseline did not increase the risk of future
obesity when controlling for baseline obesity.32 In this study, the sample was collected
from the 1994 and 1999 waves of the Alameda County cohort, including 2,123
individuals who were 50 years or older. This finding suggests a possible causal
relationship for the obesity-to-MDD direction, but not vice versa; however, to the
knowledge of the researchers, this result has not been obtained in any other research. It
has been shown that the presence of overweight or obesity in individuals with MDD is
associated with slower clinical and neuroendocrine responses to antidepressant
treatment.39 Additionally, weight loss has been associated with a significant, sustained
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reduction in the severity of MDD, with individuals achieving greater weight loss also
experiencing the largest reduction in MDD severity.38 The importance of treating MDD
is further emphasized by the correlation between the presence of a current or lifetime
MDD diagnosis, in addition to obesity, and an increased risk for the development of other
psychiatric disorders, smoking, physical inactivity, alcohol and substance abuse,
disordered eating, and other unhealthy behaviors.31, 33, 36 Although these findings did not
determine a specific causal direction in the MDD-obesity relationship, they do suggest
the dire need for a multifactorial and comprehensive approach to the treatment of MDD
and obesity, beyond pharmaceuticals, especially when the conditions are concurrently
present.
Ketogenic Diet
Traditional treatments for MDD may not always be effective in managing
physiological consequences of the condition, especially when individuals are
experiencing reduced glucose metabolism in the brain, increased levels of oxidative
stress, or have multiple comorbidities. A possible alternative or complementary treatment
for MDD would be a dietary intervention of the ketogenic diet, which is a high-fat, very
low-carbohydrate, adequate-protein eating plan. Typically, it includes an initial reduction
of net carbohydrate intake to less than 20 to 50 grams per day with a macronutrient
distribution of approximately 0-10% carbohydrate, 60-80% fat, and 10-30% protein as a
percent of total energy intake.40 This severe restriction of carbohydrates lowers glucose
availability, thereby decreasing insulin and increasing glucagon concentrations. This
creates a metabolic shift in the body away from fat storage to lipolysis and β-oxidation by
“imitating” a fasted state.41 However, in the ketogenic diet, both exogenous and
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endogenous protein and fat sources can provide energy, and glucose concentrations can
be relatively maintained without carbohydrate intake.40 The ketogenic diet’s alternative
nutrient utilization is one of its most important characteristics and may be highly
beneficial for the MDD population as they typically have significantly reduced glucose
metabolism in the brain. The subsequent sections describe the mechanisms of action
related to the ketogenic diet in brain nutrient metabolism, the production of BDNF,
regulation of oxidative stress, and weight management that could improve the
physiological consequences of MDD.
Neurophysiology.
Ketone Metabolism. As the ketogenic diet restricts carbohydrate intake to a level
at which the body is not able to maintain carbohydrate utilization throughout all tissues, it
is necessary that the body more effectively use lipids and their metabolites for energy.
When energy is mainly provided by fatty acid oxidation in cell mitochondria, large
amounts of acetyl-CoA are produced, which are then utilized, primarily in the liver, to
synthesize the ketone bodies β-hydroxybutyrate (β-HB), acetoacetate and acetone.42
Ketosis occurs when the metabolic efficiency of the Krebs, or tricarboxylic acid (TCA)
cycle, is reduced and additional acetyl-CoA is converted into ketones.42 Because the
liver does not have succinyl CoA:3- ketoacid CoA transferase, a mitochondrial enzyme
that converts acetoacetate to acetoacetyl CoA, ketone bodies are forced into the
circulatory system.43 In ketosis, the levels of the ketone bodies β-HB, acetoacetate, and
acetone are increased in the peripheral blood and urine. These ketones are delivered to
and serve as a fuel source for numerous extrahepatic tissues, including the brain.42, 44 This
process mainly occurs in metabolic states in which glucose is insufficiently available to
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fulfill its normal fuel-based functions. Higher levels of ketosis will proportionally spare
glucose from metabolism in the brain and other tissues.44 This mechanism has great
significance in conditions in which glucose availability can be severely limited, as fatty
acids are not able to cross the blood-brain barrier to provide energy. This sparing effect
of ketones for glucose in cerebral metabolism has been shown in rat models and has
demonstrated a coordinated upregulation of energy metabolic genes and an increase in
metabolic gene transcripts.44, 45 To the knowledge of the researchers, no current research
has demonstrated these findings in any human population. Despite this lack of research,
the ketogenic diet provides an alternative source of energy for the brain, which could
benefit individuals with MDD who experience significantly reduced brain glucose
metabolism.
BDNF Activity and the Ketogenic Diet. Another aspect of brain function
affected by ketone bodies is the concentration and activity of BDNF. Although no
studies have demonstrated in vivo action of ketones on the expression of BDNF in
humans, in vivo and vitro animal models have shown ketone-mediated alterations in
BDNF gene expression and protein levels.46-49 At least two models have examined the
direct effects of a ketogenic diet on BDNF activity. Genzer et al. showed an increase in
the BDNF:proBDNF ratio, whole brain and liver BDNF expression, and BDNF mRNA in
a population of C57BL/6 male mice fed an ad libitum ketogenic diet.46 This finding
suggests a ketone-induced upregulation of BDNF production, especially in the brain.
However, Vizuete et al. demonstrated that BDNF content was decreased in the corpus
striatum, but not the hippocampus, in male Wistar rats fed a ketogenic diet.48 These
conflicting results imply that a ketogenic diet may affect BDNF regulation by increasing
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total BDNF gene expression and content but reducing regional BDNF synthesis. Another
in vivo study examined the indirect effects of a ketogenic diet on BDNF activity by using
2-deoxy-D-glucose to induce ketogenesis and ketosis in 3xTgAD mice. In this study, Yao
et al. found that 2-deoxy-D-glucose-induced ketosis did not adversely affect
mitochondrial function in neurons or mixed glia and stimulated the upregulation of the
BDNF and another neurotrophic factor, nerve growth factor (NGF).49 In an in vitro study
of exercised male C57BL/6 mice, β-HB was found to increase with exercise and
coincided with an increase in BDNF expression and protein levels in cortical neurons.47
This finding is consistent with the results of the previously discussed in vivo studies, as it
suggests that β-HB is involved in the in vivo regulation of BDNF. Although these studies
have only examined animal models, they indicate that there could be benefits of using a
ketogenic diet in conditions like MDD, in which BDNF expression or protein levels are
lowered.
Oxidative Stress and the Ketogenic Diet. In addition to the previously mentioned
metabolic and neurological alterations, the ketogenic diet has been shown to have
significant impact on both systemic and brain oxidant-antioxidant systems. The theorized
neuroprotective effect of the ketogenic diet is associated with acetoacetate and β-HB and
has only been demonstrated in animal models. These studies have shown that a
ketogenic diet, via acetoacetate and β-HB action, can protect hippocampal and
dopaminergic neurons from glutamate-induced or 1-methyl-4-phenyl-1,2,3,6tetrahydropyridine (MPTP) excitotoxicity and can increase glutathione synthesis, Nrf2
protein levels, NAD(P)H dehydrogenase quinone 1 (NQO1) activity.50-53 The
upregulation of these antioxidant substrates could contribute to the ketogenic diet’s
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protective mechanism against oxidative damage and improvements in mitochondrial
redox status. Several animal studies have shown the indirect effects of the ketogenic diet
in mediating oxidative stress by decreasing reactive oxygen species (ROS) and free
radicals and enhancing mitochondrial antioxidant capacity.53-55 It is suggested that the
reduction in ROS production is achieved by improving mitochondrial uncoupling protein
activity, which reduces the membrane potential upon which the ROS production is
dependent.55 The ketogenic diet has also been shown to improve hippocampal
mitochondrial antioxidant capacity, specifically by increasing NQO1, SOD1, and GPx
expression and decreasing catalase activity in animal models.56, 57 These animal-based
studies demonstrate that the ketogenic diet has the potential for reliable antioxidant, antiinflammatory, and neuroprotective capabilities in conditions, like MDD and obesity, that
are adversely affected by systemic and neural oxidative stress and inflammation.
However, more research is needed to determine if the ketogenic diet can reliably improve
antioxidant capacity and reduce oxidative damage in humans.
Mood Changes with the Ketogenic Diet.
Several animal studies have demonstrated possible antidepressant or moodimproving properties of the ketogenic diet; however, the exact mechanisms have not been
established. Two of these studies appeared to show that a ketogenic diet, mainly through
the action of β-HB, reduced “behavioral despair” in stressor-exposed male Wistar rats
and depressive-like behaviors in stressor-exposed male C57BL/6J mice.58, 59 One severe
limitation of the study by Huang et al. is that they did not assess whether ketosis was
necessary to induce the behavioral change.59 However, similar results were replicated in
a study that conducted two parallel experiments, in which a group of male ICR mice
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received daily β-HB injections (300 mg/kg), another group received a ketogenic diet, and
both were exposed to severe stressors and compared to separate controls.60 The results of
this study demonstrated that exogenous β-HB improved depressive behaviors, and
mitigated the reduction of Histone3-lysine9-β-hydroxybutyrylation (H3k9βhb) and
BDNF. Another animal study examined the offspring of female CD-1 mice that had
followed a ketogenic diet during gestation and found that prenatal exposure to a
ketogenic diet altered the offspring’s’ neuroanatomy and improved their resistance to the
development of anxiety and depression in adulthood.61 The primary changes to
neuroanatomy in these offspring compared to controls were cerebellar volumetric
enlargement by 4.8%, a hypothalamic reduction by 1.39%, and a corpus callosum
reduction by 4.77%, relative to total brain volume. In human-based studies, ketogenic
diets have been shown to have varying effects on mood and behavior in comparison to
low-fat diets, such as decreasing markers of anxiety, but not affecting those of
depression62, demonstrating higher levels of fatigue, but lower levels of social
antagonism63, and impairing memory performance, but supporting sustained attention.64
A study conducted in a human sample by Halyburton et al. compared the effects of a lowcarbohydrate ketogenic diet to a high-carbohydrate diet on mood and cognitive
performance.65 These researchers showed that both diets were effective in improving
mood, with no difference in effectiveness, but that the low-carbohydrate ketogenic diet
improved cognitive processing speed more than the other dietary intervention. However,
the generalizability of this study is limited to “healthy, overweight and obese, young to
middle-aged adults with normal mood state and no cognitive impairment”, and not
populations with diagnosed MDD.65 This literature review is expected to further
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elucidate the influence of the ketogenic diet on improving characteristics of mood that are
specifically affected in individuals with MDD.
Obesity and the Ketogenic Diet.
While the primary purpose of this narrative review is to outline the therapeutic
potential of a ketogenic diet in treating MDD, it also seeks to confirm previously
demonstrated effects of the ketogenic diet on body composition, especially in overweight
and obese populations. Because of the elevated risk for these populations to develop
MDD, other psychiatric disorders, and chronic metabolic diseases, it would be beneficial
to identify treatments that improve both mental and metabolic health conditions. Within
the literary body of evidence, there is varying data regarding the effectiveness of the lowcarbohydrate ketogenic diets in comparison to other traditional weight-loss dietary
interventions. Numerous studies of the ketogenic diet have demonstrated significantly
greater improvements in weight loss and reductions in abdominal and visceral obesity in
comparison to low-fat 66-74 and Mediterranean75 diets. A follow-up study by Dyson et al.
determined that the weight loss effect of the ketogenic diet was higher than that of a lowfat diet immediately following the intervention and at 6 months, but that this effect was
no longer significantly different at two years after the intervention.76 Several studies
have shown improvements in body weight and obesity with the ketogenic diet but
without any comparison to a control group.77-80 The primary theory regarding the greater
effectiveness of the ketogenic diet for weight loss is that they work indirectly by
restricting total energy intake due to sustained satiety and energy expenditure, increased
fatty acid oxidation, and a sparing effect on fat-free mass.81 In contrast to this data
supporting the efficacy of the ketogenic diet, numerous studies also demonstrate that
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while the ketogenic diet does induce weight loss, it is no more effective than low-fat, the
Mediterranean, or non-ketogenic low carbohydrate diets for the treatment of obesity.72, 8193

The primary theory for the ketogenic diet having no greater effectiveness than other

traditional weight-loss diets is that all weight-loss diets have relatively similar total
energy intakes and that there is no metabolic advantage to one or more particular
macronutrients. The correlation between MDD and obesity supports further research into
and the utilization of therapies like the ketogenic diet that can improve both conditions
through multiple physiological mechanisms.
Biomarker Alterations with the Ketogenic Diet.
The association between biomarkers such as serum lipids and glucose and the
oxidative stress and inflammation induced through MDD and chronic metabolic diseases
has been well established. However, the evidence for the impact of a ketogenic dietary
intervention on these biomarkers is highly ambiguous. Based on numerous studies
examining the use of the ketogenic diet for weight-loss intervention and improvement of
metabolic risk factors, it has been shown that the ketogenic diet has more significant
effects on lipid profiles, glycemic control, and insulin resistance, and proinflammatory
markers compared to traditional weight-loss diets. Some studies have shown a serum
lipid response to a ketogenic diet that includes an increase in total cholesterol,75, 81 lowdensity lipoprotein (LDL),66, 75, 79, 83, 90-93 high-density lipoprotein (HDL),66, 69, 74, 75, 77, 79,
80, 83, 90, 92-94

and a decrease in triglycerides (TG).66, 74, 75, 77, 82-85, 93-97 Other studies have

shown different effects on serum lipids leading to unchanged or decreased HDL,73, 77, 79,
89, 95

TGs,73, 79, 80 total cholesterol,69, 73, 74, 77, 80, 94, 98 and LDL.69, 73, 74, 80, 94-97 The

alterations to glycemic control consistently show decreased serum glucose69, 75, 84, 85, 90, 92,
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or glycated hemoglobin (HbA1c),82 decreased insulin,69, 79, 90, 92 and decreased insulin

resistance.85, 86, 98 The inflammatory markers that may be decreased in individuals
following a ketogenic diet include TNF-α,97, 99, 100 interleukin-6,97, 100 interleukin-8,97
monocyte chemoattractant protein 1 (MCP1),97 E-selectin,97 intercellular adhesion
molecule 1 (I-CAM),97, 100 and C-reactive protein (CRP).90, 97, 100 However, Cardillo et al.
found no change in serum CRP following a ketogenic dietary intervention.99 These
biomarkers are an important indicator of health as they are correlated with chronic stress
and inflammation that can lead to the development of comorbid metabolic and psychiatric
conditions. Based on the research regarding the influence of the ketogenic diet on
metabolic biomarkers, the ketogenic diet may be beneficial for individuals with issues of
glycemic control; however, there is no consensus regarding improvements to lipid
markers as an effect of the ketogenic diet. Further research could provide valuable data
to this area of literature, specifically by examining the effects of the ketogenic diet on
these biomarkers in populations with MDD and other mood disorders.
Study Justification
The purpose of this review is to demonstrate the potential of the ketogenic diet to
be utilized as a medical nutrition therapy for MDD. To the knowledge of the researchers,
no past reviews have outlined how the ketogenic diet could functionally affect these
physiological mechanisms of MDD. This narrative review briefly illustrates the
prevalence of MDD, describes the physiological changes that occur from the condition,
and identifies the increased risk for the development of obesity and other metabolic
diseases. Animal models have shown the capability for the use of this diet as nutrition
therapy for MDD through utilization of lipid metabolites in brains with altered glucose
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metabolism, increased BDNF activity, and improved antioxidant capacity in the brain.
These physiological effects of the ketogenic diet support its utilization in research for
populations that have MDD and comorbid psychological and metabolic conditions. The
current state of literature presents an opportunity for psychology and nutrition researchers
to progress from animal models to examine whether these effects are observable in a
human population while further assessing mood and the psychological characteristics of
MDD. Furthermore, the advancement of knowledge in this area may help mental health
care providers and nutrition professionals to better address the individual needs of their
patients with MDD.
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Chapter II. Methodology
This research project was originally designed as a randomized controlled trial to
examine whether a 12-week high-fat, low-carbohydrate ad libitum ketogenic diet alone
reduces depression severity and improves body composition more effectively than an ad
libitum Dietary Approaches to Stop Hypertension (DASH) diet in a population of
military veterans. However, due to the COVID-19/coronavirus pandemic at the
beginning of 2020, this study was terminated and transitioned to a literature review to
eliminate any risk of infection for participants and researchers. The provided approved
methodology describes the processes through which the original dietary interventions
were supposed to be conducted.
Participants
Initially, a total of 50 male and female veterans were expected to be recruited by
public advertisement to participate in a 12-week dietary intervention. After Institutional
Review Board (IRB) approval, participants were recruited from the Martinsburg Veterans
Affairs Medical Center and its community-based outpatient clinics in the Shenandoah
Valley region of Virginia through recruitment flyers and a bulk email distributed to
James Madison University faculty, staff, and students (Appendix A). The primary
inclusion criterion for participation was status as a veteran of any branch of the United
States Armed Forces. Before recruitment was discontinued due to the COVID-19
pandemic, a total of 15 eligible individuals contacted the researchers; however, after
being provided with an outline of the study participation requirements only 7 males and 1
female (n=8) elected to proceed with the informed consent. Participants were assessed
for the presence and severity of major depressive disorder through the Beck Depression
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Inventory-II (BDI-II) (Appendix B). Before the study commencement, all participants
completed a health screening questionnaire (Appendix B), which was used to determine
whether they met the inclusion and exclusion criteria. One additional inclusion criterion
was for participants to be between the ages of 18-65 years. Participants were also eligible
to be included if they had a diagnosed anxiety disorder or post-traumatic stress disorder,
so long as major depression was a primary diagnosis as determined by a physician or
mental health professional. The use of antidepressants or anxiolytics was allowed if the
participant had been consistently using these medications for ≥ 8 weeks. Any change in
antidepressant or anxiolytic medication type during the intervention would disqualify
participants from continued participation. Participants were also able to use antidiabetic
(including insulin), antihyperlipidemic, or antihypertensive medications if they have been
consistently taken for ≥ 2 weeks, ≥ 8 weeks, and ≥ 2 weeks, respectively. Exclusion
criteria included: weight instability (± 4.5 kg in the past 6 months); use of a low or no
carbohydrate diet in the past 3 months; diagnosis of any psychological disorders other
than major depressive disorder, an anxiety disorder, or post-traumatic stress disorder; use
of mood stabilizers or antipsychotics.
The protocol and the potential risks and benefits of the study were fully explained
to all participants before they provided written informed consent. All experimental
procedures were approved by the IRB of James Madison University.
Study Design
In a parallel study design, eligible participants were randomly assigned to follow
an ad libitum low-carbohydrate ketogenic dietary intervention (LCKD) or ad libitum
Dietary Approaches to Stop Hypertension (DASH) for 12 weeks. Except for the
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prescribed dietary intervention, participants were asked to maintain their usual lifestyle
and activity throughout the study. At baseline (week 0), week 6, and week 12,
participants would attend testing after an overnight fast. Details of the data collection
methods for this testing are discussed in the following sections.
Dietary Intervention
Although both dietary interventions were prescribed as ad libitum, participants
were provided general information about adequate nutrition practices. The estimated
macronutrient distribution for each dietary intervention is as follows: the LCKD with 2530% of total energy as protein, 65-70% as fat, and 5-10 % as carbohydrate; the DASH
with 15-20% of total energy as protein, 30-35% as fat, and 50-55% as carbohydrate.
Participants in the LCKD group were to be restricted to < 50g of total carbohydrates per
day throughout the 12-week intervention to maintain their state of ketosis. To facilitate
dietary compliance, participants in both groups received individualized handouts
containing recipes, online resources, a list of foods that could assist them in meeting their
nutritional needs and foods that should be avoided, and tips for maintaining their assigned
dietary intervention (Appendix C). A consecutive four-day food record (3 weekdays, 1
weekend day) was to be collected and analyzed at weeks 0, 4, 8, and 12 either during an
in-person meeting or phone call. This analysis was to be conducted using the Nutrition
Data System for Research (NDSR) software (University of Minnesota Nutrition
Coordinating Center, Minneapolis, MN). Additionally, participants assigned to the
LCKD were supposed to complete a weekly dietary compliance checklist to ensure
adherence to the assigned diet. If participants consumed any of the listed carbohydratecontaining foods, they would log what foods and how much was consumed and report
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this information to the researchers at the end of each week. These checklists were
intended to be used by researchers to assess participants’ adherence to the assigned
dietary guidelines and to prompt a personalized dietary education session to guide the
participant back into dietary compliance if needed.
Clinical Measures
Body height was measured to the nearest 0.1 cm and body weight was measured
to the nearest 0.05 kg using a MedVue® medical weight analyzer with a stadiometer
(Detecto; Missouri). Both measures were taken while participants were barefoot and in
light clothing. Body composition, specifically fat mass, fat-free mass, and body fat
percentage were assessed using a dual-energy X-ray absorptiometry (DXA) scan
(Illuminatus DXA, Norland at Swissray; Fort Atkinson, WI), while participants were
supine in light clothing with no metal or footwear. Blood pressure was assessed by
researchers using a sphygmomanometer, in a supine position, immediately following the
DXA scan. Blood pressure measurement procedures followed the American College of
Sports Medicine’s Guidelines for Exercise Testing and Prescription.101 These clinical
measures were to be collected at weeks 0, 6, and 12.
Questionnaires
The severity of major depressive disorder was assessed using the Beck
Depression Inventory-II (BDI-II), which is a 21-question self-report inventory and a
reliable and well-validated measure (Appendix B).102 A high score on the BDI-II
indicates a higher severity of the depressive state. The presence and severity of anxiety
were assessed using the Beck Anxiety Inventory (BAI), which is a 21-question self-report
inventory that is also a reliable and well-validated measure (Appendix B).103 The
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International Physical Activity Questionnaire-Long Form (IPAQ-L) is a selfadministrable, 27-question measure, which produces estimates of physical activity in five
domains: work, transportation, household, leisure, and sedentary time (Appendix B). The
IPAQ-L has demonstrated good reliability and validity in research.104 These
questionnaires were to be completed by the participants during the laboratory testing
sessions at weeks 0, 6, 12.
Biochemical Analysis
Fasted capillary blood samples were collected through fingersticks using blood
lancets. Fasting blood glucose, a full serum lipid profile [including high-density
lipoprotein (HDL), low-density lipoprotein (LDL), triglycerides (TG), total cholesterol],
and serum ketone measures were taken and analyzed using a CardioChek PLUS Blood
Analyzer (PTS Diagnostics; Indiana) and the appropriate testing strips. These measures
were to be completed at weeks 0, 6, and 12. Additionally, urinary ketones were to be selfassessed daily by participants assigned to the LCKD, using URiSCAN® Ketones Urine
Test Strips (YD Diagnostic Corp; South Korea). These results were to be recorded in a
written log and provided weekly to researchers to assess the presence of ketosis and
ensure LCKD dietary compliance. Each week, LCKD participants were expected to meet
compliance with ketosis (positive urinary ketone test) for ≥ 6 days, or they would be
removed from the study.
Statistical Analysis
The sample size was determined using the National Statistical Service Sample
Size Calculator (Australian Bureau of Statistics). The confidence level was set at 95%.
Based on the total population of U.S. military veterans (n=4,914,208), any sample of
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these individuals is expected to yield a 0.069 proportion of individuals with MDD.105 It
was determined that the sample size for this study requires a minimum of 25 and a
maximum of 99 participants to achieve confidence intervals of 0.10 and 0.05
respectively.
Before hypothesis testing, data was to be examined for normality using the
Shapiro-Wilk test. Statistical analyses were to be performed with SPSS software (version
26.0; IBM; New York). Between-group differences in baseline characteristics were to be
assessed using independent t-tests for continuous variables and Pearson chi-square test
for categorical variables. The effects of the dietary intervention on psychological and
biochemical variables were to be determined using repeated-measures analysis of
variance (ANOVA) with time as the within-subject factor and diet (LCKD vs. DASH)
and sex as between-subject factors. Statistical significance was to be set at P < 0.05.
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Chapter III. Manuscript
Therapeutic Potential of a Ketogenic Diet in the Treatment of
Major Depressive Disorder: A Narrative Review
ABSTRACT
Major depressive disorder (MDD) is the second most common mental health condition
and a leading cause of disability in the world. It is theorized that MDD develops from a
combination of biological, psychological, and social stressors. The condition is typically
treated using pharmaceuticals and psychotherapy. However, not all individuals with
MDD have access to or choose to use these treatments, or may prefer to incorporate
therapeutic lifestyle changes such as exercise, sleep, and healthy eating. Even with
treatment, MDD can alter brain structure and function, leading to the development of
comorbid mental health and chronic metabolic conditions like obesity, cardiovascular
disease, or diabetes. Physiological mechanisms that can be significantly affected by
MDD episodes include brain glucose metabolism, brain-derived neurotrophic factor
(BDNF) production and activity, and antioxidant function. This paper reviews existing
literature to examine these components of the pathophysiology of MDD and outline how
treatments could functionally improve the condition. Most research has examined the
relationship between nutrition and MDD utilizing traditional interventions, like low-fat
diets, but more recent studies have explored alternative nutrition therapies. Animalmodels have shown potential for the use of the ketogenic diet as nutrition therapy for
MDD by demonstrating improved metabolism of alternative nutrients, increased BDNF
activity, and improved antioxidant capacity in the brain. However, to date, there are no
studies that examine the effects of a ketogenic diet on a human population with MDD.
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Future research is warranted to determine whether a ketogenic diet is a safe and reliable
medical nutrition therapy for MDD.
INTRODUCTION
Major depressive disorder (MDD), also known as clinical or major depression,
has a significant impact on the personal, social, familial, and occupational function of
millions of individuals in the US and the rest of the world. According to the World
Health Organization (WHO), MDD was the fourth highest cause of disability in the world
in 2013 and is on course to be the second highest by the end of 2020.1 While the global
lifetime incidence of MDD has been estimated to be between 15 to 20%, there was a 10year prevalence rise from 6.6% in 2005 to 7.3% in 2015.1, 2 The incidence of MDD
among the general population is based on a variety of demographic, socioeconomic, and
lifestyle factors. Research has also revealed that depression is two to three times more
common in individuals who already have multimorbidities compared to those with one or
no chronic physical conditions.3 This data indicates a potential risk for a cyclical or
synergistic pattern of depression and chronic disease, due to the inflammatory effect that
depression has on human physiology.
With research indicating that diet, sleep, and exercise all have a significant impact
on the development, progression, and management of depression, there is an opportunity
for creating non-pharmacological interventions that address these factors, especially
among those individuals not currently following any treatments for depression.4 To date,
most research examining how nutrition can improve mental health has utilized dietary
interventions that emphasize a higher intake of fruits, vegetables, and whole grains,
following a low-fat diet or exchanging high saturated fat foods for those high in
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unsaturated fats, or limiting the consumption of foods that are highly processed or contain
high amounts of added sugars.5 However, with the continued rise in the prevalence of
MDD, it would be beneficial to continue research into the effects of nontraditional dietary
interventions that do not necessarily strictly follow to these typical eating patterns.
Therefore, this narrative review will describe the pathophysiology of MDD, including
brain nutrient metabolism and oxidative stress, and the relationship between MDD and
obesity. Additionally, it will review current research regarding the high-fat, lowcarbohydrate ketogenic diet and its mechanistic action on neurophysiological systems
that are dysregulated in MDD to outline the therapeutic potential of this type of dietary
intervention in the treatment of the condition.
METHODS
An initial literature search was conducted between February 5, 2018 and May 4,
2018, in addition to an updated search between March 2, 2020 and June 5, 2020, using
three databases. The databases (PubMed, Cumulative Index to Nursing and Allied Health
Literature [CINAHL], and Cochrane Library) were searched using the following terms
either singularly or in combination: Ketogenic Diet, Ketone Metabolism, Major
Depressive Disorder or Depression, Brain-derived Neurotrophic Factor, Oxidative
Stress, and Obesity. The review includes intervention studies with no restrictions on the
population examined but is limited to research published after January 1, 2000 and
written in the English language. Articles were excluded if the primary dietary
intervention utilized a low carbohydrate non-ketogenic diet or exogenous ketone source,
or if the sample size was less than 50 human participants. The research design was not a
factor for exclusion, due to the variability of methodologic limitations or the lack of
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control groups within the reviewed studies. Figure 1 summarizes the processes of this
literature search, and Table 1 presents a summary of the literature.

DISCUSSION
Neuropathology of Major Depressive Disorder
To better comprehend the prevalence and effects of MDD, it is important to
understand its status as a mental health condition and how it is categorized and diagnosed
by mental health professionals. MDD is classified as a neuropsychiatric mood disorder
and is characterized by a persistently depressed mood or loss of interest in daily
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activities.6 A diagnosis typically designates the condition as either an isolated or
recurrent episode, and will classify the episode as mild, moderate, or severe.6 MDD is
considered to be caused by a combination of various biological, psychological, and social
stressors, which can create an inflammatory state within the body that affects multiple
physiological organ systems. These factors can also alter some of the major brain
functions including brain glucose metabolism, regulation of brain-derived neurotrophic
factor (BDNF), and antioxidant activity.
Glucose metabolism. Although glucose is typically the main source of energy
for the brain, there are significant alterations in the mechanisms of glucose metabolism in
populations affected by major depression. Several studies examining individuals with
MDD have demonstrated regional glucose hypometabolism and metabolic asymmetry in
various regions of the brain, including the left prefrontal cortex, cerebellum, left anterior
cingulate, right insular cortex, right claustrum, right anteroventral caudate and putamen,
right middle temporal gyrus, and right superior temporal gyrus.7-9 These alterations have
been associated with the progression of depressive episodes as individuals with more
severe depression have demonstrated lower global cerebral glucose metabolic rates.10 It
has also been shown that successful pharmacological treatment with various
antidepressants can increase glucose utilization in the left prefrontal cortex; although, this
may not improve whole frontal glucose metabolism.8 Holthoff et al. even reported
decreases in regional glucose metabolism in remitted MDD patients treated with selective
serotonin reuptake inhibitors (SSRIs) and serotonin-norepinephrine reuptake inhibitors
(SNRIs).7 These results demonstrate that specific antidepressant treatments may not
induce long-term changes to or may have detrimental effects on cerebral glucose
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metabolism. A possible causal link between MDD and decreased cerebral glucose
metabolism was illustrated by Kahl et al. showing that elevated DNA methylation of
GLUT1 in unremitted MDD patients lowered GLUT1 expression in brain cells, but could
be reversed through MDD remission.11 These findings indicate that glucose uptake from
blood vessels into the brain may be compromised in both untreated and treated MDD and
suggest that the utilization of other energy sources could potentially improve cerebral
metabolism for these individuals.
BDNF. Although brain metabolic dysfunction is an important factor in the
pathophysiology of depression, there are other noted alterations in brain function, such as
changes to the activity of BDNF. BDNF is the most abundant neurotrophin in the
nervous system and is involved in the development and regulation of neuronal systems,
neurotransmitter activity, and neuroplasticity.12, 13 Individuals with MDD have been
shown to have significantly lower concentrations of serum BDNF in comparison to
healthy controls.12, 14-19 Lower serum BDNF levels have also been reported during
recurrent depressive episodes as compared to first episodes,14 in individuals with longterm MDD (≥1 year) as compared to short-term MDD (<1 year),20 and in individuals with
MDD as compared to individuals with dysthymia.17 Sözeri-Varma et al. did find one
contrasting result by demonstrating that there was no significant difference in serum
BDNF levels between individuals in their first and recurrent MDD episodes.15 Regarding
the correlation between MDD treatment and BDNF activity, it has been demonstrated
that antidepressants can increase serum BDNF levels in individuals with MDD.12, 16, 19
While these findings do not indicate that antidepressants only treat MDD by improving
BDNF levels, it has been suggested that low BDNF levels play an important role in the
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pathophysiology of MDD and other affective disorders.12, 16, 19 Although most data
appears to support this hypothesis, there is no evidence for directionality in this
relationship, and some conflicting data has been shown between serum BDNF levels and
the severity of MDD.14, 15, 20 The correlation between improvements to reduced BDNF
levels and the severity of MDD symptoms warrants additional research, especially
regarding treatments and interventions that can improve both of these conditions.
Oxidative Stress. Other prevalent alterations to brain function in MDD can
occur through the action of oxidative stress, which can have significant effects on brain
structure and metabolism, and neuronal interaction. Markers of oxidative stress and
reduced antioxidant function have been repeatedly noted in individuals with MDD
compared to healthy controls.21-25 The major brain antioxidant glutathione, its
complementary enzyme glutathione peroxidase (GPx), and the detoxifying brain isozyme
glutathione S-transferase Mu 1 (GST Mu 1) were shown to be significantly lowered in
post-mortem brain tissues of individuals with MDD, bipolar disorder, and
schizophrenia21, 26 and the serum of living individuals with MDD.22, 25 However, there
has been a report that found no difference in GPx activity between individuals with MDD
and healthy controls.23 While these enzymes are typically reduced during MDD, there
have also been some reports of increased activity of the antioxidant enzymes glutathione
reductase,22, 26 superoxide dismutase (SOD),22, 26, 27 and catalase.23, 27 However, Rybka et
al. did find decreased SOD activity in individuals with MDD in comparison to healthy
controls.25 Additionally, some of these antioxidant activities have not been shown to
improve or have been slightly suppressed with the pharmacological treatment of MDD.23,
26, 27

These findings illustrate that oxidative stress in psychiatric conditions, including
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MDD, is likely exacerbated by antioxidant dysregulation and dysfunction. Markers of
oxidative stress, such as malondialdehyde, 8-OH 2-deoxyguanosine, interleukin-6, tumor
necrosis factor-α (TNF-α), F2-isoprostanes, neopterin have also been found in elevated
levels in individuals with MDD, and some have been associated with decreased
effectiveness of antidepressant treatments.24-26 Interleukin-6 levels, however, have been
shown to decrease with SSRI treatment.24 The relative ineffectiveness of several
antidepressant treatments for improving oxidative stress in MDD suggests that other
therapeutic methods should be examined for the limitation of prooxidant and
enhancement of antioxidant systems.
Obesity. Due to its similar relationship with increased oxidative stress and
systemic inflammation, it is important to also examine obesity and how it correlates with
MDD. There have been numerous large-scale, cross-sectional epidemiological and
observational studies that have examined this relationship, and have demonstrated a
positive correlation between obesity and MDD.28-32 Several studies have reported that
this association occurs mainly between MDD and severe or class III obesity (body mass
index ≥ 40 kg/m2).28, 33, 34 Despite this significant correlation, no causal direction of the
MDD-obesity relationship has been officially established. It has been shown that the
presence of overweight or obesity in individuals with MDD can significantly slow their
clinical and neuroendocrine responses to antidepressant treatment.35 Additionally, weight
loss has been associated with a significant, sustained reduction in the severity of MDD,
with individuals achieving greater weight loss also experiencing the largest reduction in
MDD severity.34 The importance of treating MDD is further emphasized by the
correlation between the presence of a current or lifetime MDD diagnosis, in addition to
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obesity, and an increased risk for the development of other psychiatric disorders,
smoking, physical inactivity, alcohol and substance abuse, disordered eating, and other
unhealthy behaviors.28, 30 Although these findings did not determine a specific causal
direction in the MDD-obesity relationship, they do suggest the dire need for a
multifactorial and comprehensive approach to the treatment of MDD and obesity, beyond
pharmaceuticals, especially when the conditions are concurrently present.
Effects of a Ketogenic Diet on Neurophysiology
Traditional treatments for MDD may not always be effective in managing
physiological consequences of the condition, especially reduced glucose metabolism in
the brain, decreased BDNF levels, increased levels of oxidative stress, or comorbid
chronic diseases. A possible alternative or complementary treatment for MDD would be a
dietary intervention focusing on the ketogenic diet, which is a high-fat, very lowcarbohydrate, adequate-protein eating plan. Typically, it includes an initial reduction of
net carbohydrate intake to less than 20-50 grams per day with a macronutrient
distribution of approximately 0-10% carbohydrate, 60-80% fat, and 10-30% protein as a
percent of total energy intake.36 This severe restriction of carbohydrates imitates a
“fasted state” by lowering glucose availability, which decreases insulin and increases
glucagon concentrations and creates a metabolic shift in the body from fat storage to
lipolysis and β-oxidation.37 However, in the ketogenic diet, both exogenous and
endogenous protein and fat sources can provide energy, and glucose concentrations can
be relatively maintained without carbohydrate intake.36 The ketogenic diet’s alternative
nutrient utilization is one of its most important characteristics and may be beneficial for
individuals with MDD as they typically have reduced glucose metabolism in the brain.
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The subsequent sections describe the mechanisms of action related to the ketogenic diet
in brain nutrient metabolism, the production of BDNF, regulation of oxidative stress, and
weight management that could improve some of the other physiological consequences of
MDD.
Ketone Metabolism. As the ketogenic diet restricts carbohydrate intake to a level
at which the body is not able to maintain carbohydrate utilization throughout all tissues, it
is necessary that the body more effectively use lipids and their metabolites for energy.
When energy is mainly provided by fatty acid oxidation in cell mitochondria, large
amounts of acetyl-CoA are produced, which are then utilized, primarily in the liver, to
synthesize the ketone bodies β-hydroxybutyrate (β-HB), acetoacetate and acetone.38
Ketosis occurs when the metabolic efficiency of the Krebs, or tricarboxylic acid (TCA)
cycle, is reduced and additional acetyl-CoA is converted into ketones.38 Because the
liver does not have succinyl CoA:3- ketoacid CoA transferase, a mitochondrial enzyme
that converts acetoacetate to acetoacetyl CoA, ketone bodies are forced into the
circulatory system.39 In ketosis, the levels of the ketone bodies β-HB, acetoacetate, and
acetone are increased in the peripheral blood and urine. These ketones are delivered to
and serve as a fuel source for numerous extrahepatic tissues, including the brain.38, 40
Higher levels of ketosis will proportionally spare glucose from metabolism in the brain
and other tissues.40 This mechanism has great significance in conditions in which
glucose availability can be severely limited, as fatty acids are not able to cross the bloodbrain barrier to provide energy. This sparing effect of ketones for glucose in cerebral
metabolism has been shown in rat models and has demonstrated a coordinated
upregulation of energy metabolic genes and an increase in metabolic gene transcripts.40, 41
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To the knowledge of the researchers, no current research has demonstrated these findings
in any human population. Despite this lack of research, the ketogenic diet provides an
alternative source of energy for the brain, which could benefit individuals with MDD
who experience significantly reduced brain glucose metabolism.
BDNF Activity and the Ketogenic Diet. Another aspect of brain function
affected by ketone bodies is the concentration and activity of BDNF. Although no
studies have demonstrated in vivo action of ketones on the expression of BDNF in
humans, in vivo and vitro animal models have shown ketone-mediated alterations in
BDNF gene expression and protein levels.42-44 Genzer et al. showed an increase in the
BDNF:proBDNF ratio, whole brain and liver BDNF expression, and BDNF mRNA in a
population of C57BL/6 male mice fed an ad libitum ketogenic diet.42 This finding
suggests a ketone-induced upregulation of BDNF production, especially in the brain.
However, Vizuete et al. demonstrated that BDNF content was decreased in the corpus
striatum, but not the hippocampus, in male Wistar rats fed a ketogenic diet.44 These
conflicting results imply that a ketogenic diet may affect BDNF regulation by increasing
total BDNF gene expression and content but reducing regional BDNF synthesis. In an in
vitro study of exercised male C57BL/6 mice, β-HB was found to increase with exercise
and coincided with an increase in BDNF expression and protein levels in cortical
neurons.43 This finding is consistent with the results of the previously discussed in vivo
studies, as it suggests that β-HB is involved in the in vivo regulation of BDNF. Although
these studies have only examined animal models, they indicate that there could be
benefits of using a ketogenic diet in conditions like MDD, in which BDNF expression or
protein levels are lowered.
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Oxidative Stress and the Ketogenic Diet. In addition to the previously
mentioned metabolic and neurological alterations, the ketogenic diet has been shown to
have significant impacts on both systemic and brain oxidant-antioxidant systems. The
theorized neuroprotective effect of the ketogenic diet is associated with acetoacetate and
β-HB and has only been demonstrated in animal models. These studies have shown that
a ketogenic diet, via acetoacetate and β-HB action, can protect hippocampal and
dopaminergic neurons from glutamate-induced or 1-methyl-4-phenyl-1,2,3,6tetrahydropyridine (MPTP) excitotoxicity and can increase glutathione synthesis and
NAD(P)H dehydrogenase quinone 1 (NQO1) activity.45-47 The upregulation of these
antioxidant substrates could contribute to the ketogenic diet’s protective mechanism
against oxidative damage and improvements in mitochondrial redox status. An animal
study showed the indirect effects of the ketogenic diet in mediating oxidative stress by
decreasing the production of reactive oxygen species (ROS) and increasing gene
expression of cytosolic and mitochondrial antioxidants.47, 48 It is suggested that the
reduction in ROS production is achieved by improving mitochondrial uncoupling protein
activity, which reduces the membrane potential upon which the ROS production is
dependent.48 The ketogenic diet has also been shown to improve hippocampal
mitochondrial antioxidant capacity, specifically by increasing NQO1, SOD, and GPx
expression and decreasing catalase activity in animal models.49, 50 These animal-based
studies demonstrate that the ketogenic diet has the potential for reliable antioxidant, antiinflammatory, and neuroprotective capabilities in conditions, like MDD and obesity, that
are adversely affected by systemic and neural oxidative stress and inflammation.
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However, more research is needed to determine if the ketogenic diet can reliably improve
antioxidant capacity and reduce oxidative damage in humans.
Mood Changes with the Ketogenic Diet. Several animal studies have
demonstrated possible antidepressant or mood-improving properties of the ketogenic diet;
however, the exact mechanisms have not been established. One of these studies appeared
to show that a ketogenic diet, mainly through the action of β-HB, reduced “behavioral
despair” in stressor-exposed male Wistar rats.51 Another animal study examined the
offspring of female CD-1 mice that had followed a ketogenic diet during gestation and
found that prenatal exposure to a ketogenic diet altered the offspring’s neuroanatomy and
improved their resistance to the development of anxiety and depression in adulthood.52
The primary changes to neuroanatomy in these offspring compared to controls were
increased cerebellar volume and a reduction in the hypothalamic and corpus callosum. A
study conducted in a human sample by Halyburton et al. compared the effects of a lowcarbohydrate ketogenic diet to a high-carbohydrate diet on mood and cognitive
performance.53 These researchers showed that both diets were effective in improving
mood, with no difference in effectiveness, but that the low-carbohydrate ketogenic diet
improved cognitive processing speed more than the other dietary intervention. However,
the generalizability of this study is limited to “healthy, overweight and obese, young to
middle-aged adults with normal mood state and no cognitive impairment”, and not
populations with diagnosed MDD.53 Further research is warranted to determine the
influence of the ketogenic diet on improving characteristics of mood that are specifically
affected in individuals with MDD.
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Obesity and the Ketogenic Diet. While the primary purpose of this narrative
review is to outline the therapeutic potential of a ketogenic diet in treating MDD, it also
seeks to confirm previously demonstrated effects of the ketogenic diet on body
composition, especially in overweight and obese populations. Because of the elevated
risk for these populations to develop MDD, other psychiatric disorders, and chronic
metabolic diseases, it would be beneficial to identify treatments that can improve
conditions that affect both mental and metabolic health. Within the literary body of
evidence, there is varying data regarding the effectiveness of the low-carbohydrate or
ketogenic diets in comparison to other traditional weight-loss dietary interventions.
Several studies of the ketogenic diet have demonstrated significantly greater
improvements in weight loss and reductions in abdominal and visceral obesity in
comparison to low-fat diets.54-56 In contrast to this data supporting the efficacy of the
ketogenic diet, numerous studies also demonstrate that while the ketogenic diet does
induce weight loss, the diet’s effect is no different than that of a low-fat diet for the
treatment of obesity.57-62 The primary theory for the ketogenic diet having no greater
effectiveness than other traditional weight-loss diets is that all weight-loss diets have
relatively similar total energy intakes and that there is no metabolic advantage to one or
more particular macronutrients. The correlation between MDD and obesity supports
further research into and the utilization of therapies like the ketogenic diet that can
improve both conditions through multiple physiological mechanisms.
Biomarker Alterations with the Ketogenic Diet. The association between
biomarkers such as serum lipids and glucose and the oxidative stress and inflammation
induced through MDD and chronic metabolic diseases has been well established.
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However, the evidence for the impact of a ketogenic dietary intervention on these
biomarkers is highly ambiguous. Based on numerous studies examining the use of the
ketogenic diet for weight-loss intervention and improvement of metabolic risk factors, it
has been shown that the ketogenic diet has more significant effects on lipid profiles,
glycemic control, and insulin resistance compared to traditional weight-loss diets. Some
studies have shown a serum lipid response to a ketogenic diet that includes an increase in
low-density lipoprotein (LDL),54, 57, 60, 61 an increase in high-density lipoprotein (HDL),54,
57, 60-63

and a decrease in triglycerides (TG).54, 56, 57, 59-62 Other studies have shown

different effects on serum lipids leading to unchanged or decreased HDL,59 total
cholesterol,56, 59, 62, 63 and LDL.56, 59, 62, 63 Alterations to glycemic control typically show
decreased serum glucose,58, 60-63 decreased insulin,60, 61 and decreased insulin resistance.58,
63

These biomarkers are an important indicator of health as they are correlated with

chronic stress and inflammation that can lead to the development of comorbid metabolic
and psychiatric conditions. Based on the research regarding the influence of the
ketogenic diet on metabolic biomarkers, the ketogenic diet may be beneficial for
individuals with issues of glycemic control; however, there is no consensus regarding
improvements to lipid markers as an effect of the ketogenic diet. Further research could
provide valuable data to this area of literature, specifically by examining the effects of the
ketogenic diet on these biomarkers in populations with MDD and other mood disorders.
CONCLUSIONS
This narrative review illustrates that MDD is a prevalent health condition that in
addition to adverse mood and behavioral changes, results in numerous physiological
alterations and creates a risk for the development of obesity and other chronic metabolic

40

diseases. It is of vital importance to develop novel therapies that have the potential to
utilize multiple mechanisms of action to treat this condition with long-term success. The
ketogenic diet is a specific intervention that could prove effective in reducing the severity
of depression, improving body composition, and attenuating the effects of several chronic
diseases. Although the ketogenic diet has been shown to have varying effects on mood in
humans, animal models show promise in the use of this diet as nutrition therapy for MDD
through alternate nutrient utilization of lipid metabolites, increased BDNF activity, and
improved antioxidant capacity in the brain. The current state of literature presents an
opportunity for psychology and nutrition researchers to progress from animal models to
examine whether these effects are observable in a human population while assessing
mood state and psychological characteristics of MDD.
The ketogenic diet may be beneficial for other diseases or disorders in which
improvements in systemic inflammation also reduce the severity of the condition. The
research concerning the effectiveness of the ketogenic diet for body composition
improvement consistently demonstrates that the diet induces total weight and fat mass
loss; however, conflict in the literature does exist as to whether the ketogenic diet is more
effective than traditional weight-loss dietary interventions in the short- and long-term,
and as to which populations would benefit from its implementation. As the ketogenic
diet has rarely been shown to be less effective, it has potential use for populations with all
levels of overweightness and obesity, although concerns with adherence and
sustainability of this dietary pattern do exist. This narrative review has also demonstrated
that the ketogenic diet can improve biomarkers of glycemic control and inflammation;
however, there is some disagreement about its effect on lipid-based biomarkers of
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cardiovascular disease. Future research should continue to examine the nutritional
consequences of the ketogenic diet through the analysis of changes to metabolic
biomarkers.
The potential physiological outcomes of the ketogenic diet support its application
in research for populations that are at risk for or have comorbid psychological and
metabolic conditions. Integration of the ketogenic diet into other lifestyle improvement
and weight loss strategies may prove particularly effective for these populations as
multifactorial approaches are more effective for treating comorbid conditions that affect
multiple physiological systems. However, future research first needs to employ
randomized controlled trials to thoroughly examine the short- and long-term
psychological, physiological, and metabolic effects of a ketogenic diet in a population
with MDD. These studies should consider possible confounding variables, such as
psychiatric and metabolic comorbidities, previous antidepressant treatment, race and
ethnicity, sex and gender, age, and previous use of other nutrition therapies. If the
ketogenic diet proves to be safe, reliable, and effective as a nutrition therapy for MDD,
further research could explore the different responses to the ketogenic diet based on the
severity of MDD and length of the episode or history of recurrence, and should include a
long-term follow up to assess the sustainability of these desire outcomes. Although
further research is warranted before nutrition therapy recommendations can be
established, both mental health and nutrition professionals should consider the
therapeutic potential of the ketogenic diet for individuals with MDD or multimorbidities
that are not receptive or responsive to traditional treatments.
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Table 1. Studies investigating the ketogenic diet and characteristics of MDD
Intervention

Primary Outcome(s)

Results/conclusions

Bazzano and
colleagues
(2014)56

Reference

RCT

Design

148 adults
Ages 22-75 y
BMI 30-45kg/m2

Participants

12-months diet
Low carbohydrate diet (LCD): <
40 g carbohydrate / day
Low Fat diet (LFD): < 30% of total
kcal from fat, <7% from saturated
fat

Body weight
Fat mass
Serum high-density lipoprotein (HDL)
Serum Triglycerides (TGs)
Plasma glucose
Serum C-reactive protein (CRP)

Bough and
colleagues
(2006)41

RCT

57 male SpragueDawley rats, ~40 days
old

3-week diet
Kcal-restricted Ketogenic diet
(KD): BioServ F3666
Normal, ad libitum control diet
(Purina 5001)

Plasma Beta-hydroxybutyrate (β-HB)
Plasma glucose
Cerebral metabolites and nucleotides
Enzyme activity
Mitchondrial count

Brinkworth and
colleagues
(2009)58

RCT

107 adults
Ages 18-65y
Abdominal obesity and
one metabolic
syndrome risk factor

Body weight
Fat mass (FM)
Fat-free mass (FFM)
Plasma glucose
Serum total cholesterol (TC)
Serum High density lipoprotein (HDL)
Serum Low density lipoprotein (LDL)
Serum Triglycerides (TGs)
Blood glucose

Dashti and
colleagues
(2004)63

Pre-test
/Post-test

83 obese (39 males, 44
females)
BMI > 35 kg/m2

12-month diet
Isocaloric diets with mild kcal
restriction: 1430 kcal for females,
1675 kcal for males
Very low carbohydrate diet
(VLCD; 4% carbohydrate, 35%
protein, 61% fat/20% saturated fat)
Low fat diet (LFD; 46%
carbohydrate, 24% protein, 30%
fat)
24-week ketogenic diet
First 12 weeks: 20-30g total
carbohydrate and 80-100g protein,
emphasis on poly- and
monounsaturated fats for fat intake
Second 12 weeks: increase to 4050 g carbohydrate
Daily multivitamin/mineral

LCD group experienced greater weight loss
Fat mass decreased more in the LCD group
HDL was increased more in the LCD group
TGs were decreased more in the LCD group
Plasma glucose was not changed for either
group
CRP was reduced more in the LCD group
KD was associated with upregulation of
metabolic gene transcripts (protein metabolism,
glycolysis, tricarboxylic acid, oxidative
phosphorylation)
No difference in activity of energy metabolic
enzymes between groups
KD was associated with an increased number of
mitochondrial profiles in the hippocampus
KD was associated with hippocampal synaptic
transmission that was resistant to low glucose
availability
Both diets resulted in weight loss and a
decrease in FM, with no differences between
groups
VLCD was associated with greater decrease in
FFM than the LFD
Blood glucose was decreased in both groups
TC, LDL, HDL were increased more in the
VLCD group
TGs decreased more in the VLCD group

Body weight/BMI
Serum total cholesterol (TC)
Serum High density lipoprotein (HDL)
Serum Low density lipoprotein (LDL)
Serum Triglycerides (TGs)
Blood glucose

Body weight decreased during all stages of diet
TC, LDL, and TGs decreased from baseline to
post-test
HDL increased from baseline to post-test
Blood glucose decreased from baseline to posttest
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Table 1. Studies investigating the ketogenic diet and characteristics of MDD
Reference

Design

Participants

Intervention

Primary Outcome(s)

Results/conclusions
All diets experienced weight loss, but there was
no difference between groups
LDL decreased in both LFD groups, and
increased in both LCD groups
TGs decreased for all groups, but there was no
difference between groups
HDL increased for all groups, but there was no
difference between groups
Fasting glucose decreased for three groups, but
not the LCD-IS group, and there was no
difference between groups
HFD was associated with increases in brain and
liver BDNF expression
KD was associated with increases in
BDNF:proBDNF ratio, whole brain and liver
BDNF expression, and BDNF mRNA in the
brain
Ketogenic diet was associated with decreased
3NT expression and increased 4HNE, NQO1
and SOD1 expression
Ketogenic diet was associated with an increase
in protein expression of cytosolic and
mitochondrial antioxidants
Ketogenic was associated with a decrease in
markers of oxidative damage
LCHF diet was associated with an increase in
plasma ketones
LCHF diet group experience greater weight loss
than the HCLF diet group
Both diets should a significant improvement in
BDI, POMS, and SAI scores, but there was no
difference between groups
DSB scores increased in both groups
LCHF diet decreased IT score more than the
HCLF diet

Gardner and
colleagues
(2016)61

RCT

61 adults
Ages 18-50y
BMI 28-40kg/m2
Insulin resistant (IR) or
sensitive (IS)

6-month diet
Low Fat diet (LFD): 20 g fat / day
Low Carbohydrate diet (LCD): 20
g digestible carbohydrate/ day
4 groups: LFD-IR, LFD-IS, LCDIR, and LCD-IS

Body weight change
Plasma High density lipoprotein
(HDL)
Plasma Low density lipoprotein (LDL)
Plasma Triglycerides (TGs)

Genzer and
colleagues
(2016)42

RCT

96 C57BL/6 male mice,
4wk old

BDNF mRNA expression

Greco and
colleagues
(2016)49

RCT

36 male SpragueDawley rats
35 days old

Halyburton and
colleagues
(2007)53

RCT

121 adults, overweight
or obese
Age 24-64 y
BMI 26-43 kg/m2

Jarrett and
colleagues
(2008)47

RCT

14 male P28 rats,
adolescents

2-week Ad libitum low-fat diet
(LFD)
6 groups: 8-week ad libitum LFD,
restricted feeding LFD (RF-LFD),
high fat diet (HFD), RF-HFD,
ketogenic diet (KD), or RF-KD
6-24hours diet
Ketogenic diet (8.4% protein,
78.8% fat, 0.8% carbohydrate, 5%
fiber)
Standard diet (18.6% protein, 6.2%
fat, 59.8% carbohydrate, 4.8 fiber)
Controlled cortical impact (CCI)
surgery or placebo
8-week diet
Low Carbohydrate High Fat
(LCHF) diet (35% protein, 61%
fat, 20% saturated fat, 4%
carbohydrate)
High Carbohydrate Low Fat
(HCLF) diet (24% protein, 30%
fat, <8% saturated fat, 46%
carbohydrate)
Both diets isocaloric and with 30%
energy requirement restriction
3-week diet
Ketogenic diet (Bio-Serv F3666)
Control Diet (Bio Serv F3517)
Diets were isocaloric and 90% of
daily requirements

3-nitrotyrosine (3NT)
4-hydroxynonenol (4-HNE)
expression
NAD(P)H dehydrogenase quinone 1
(NQO1) expression
Superoxide Dismutase (SOD1 and 2)
expression
Beck Depression Inventory (BDI)
Profile of Mood States (POMS)
Spielberger State Anxiety Inventory
(SAI)
Cognitive function: digit span
backwards (DSB) and inspection time
(IT) tests

Serum Β-HB
Glutathione (GSH) concentration
Reduced coenzyme A (CoASH) levels
Glutamate cysteine ligase (GCL) levels

Ketogenic diet was associated with an
upregulation of GSH synthesis
Ketogenic diet was associated with an increase
in CoASH and GCL activity
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Table 1. Studies investigating the ketogenic diet and characteristics of MDD
Reference

Design

Participants

Lim and
colleagues
(2010)57

RCT

104 adults
1 or more
cardiovascular disease
risk factor
BMI 28-40 kg/m2

Marosi and
colleagues
(2016)43

RCT

16 male C57BL/6 mice

Milder and
colleagues
(2010)45

RCT

12 male SpragueDawley rats

Murphy and
colleagues
(2004)51

RCT

40 adult male Wistar
rats

Intervention

Primary Outcome(s)

Results/conclusions

15-month diet: 3 months with
counseling, 12 months selfmaintenance
All diets 1550kcal
Very Low Carbohydrate (VLC;
35% protein/60% fat/20%
saturated fat/4% carbohydrate)
Very Low Fat (VLF; 20%
protein/10% fat /3% saturated fat
/70% carbohydrate)
High Unsaturated Fat (HUF; 20%
protein/ 30% fat/ 6 saturated
fat/8% polyunsaturated fat/ 50%
carbohydrate)
Control
6-week diet
2 groups: with (n=8) and without
(n=8) running wheels
Food and water ad libitum
12h light/12h dark cycle

Body weight
Blood pressure (BP)
Serum High density lipoprotein (HDL)
Serum Low density lipoprotein (LDL)
Serum Triglycerides (TGs)
Blood glucose
Plasma ketones

All diets, excluding control, experienced weight
loss with no differences between groups
VLC was associated with increases in LDL and
HDL, while other diets decreased both factors
VLC was associated with a decrease in TGs,
while other diets increased this factor
All diets, excluding control, experienced a
decrease in BP with no differences between
groups

Plasma 3-hydroxybutyrate (3-HB)
concentration
Neuronal oxygen consumption and
glycolytic rate
Neuronal BDNF concentrations

1-, 3-day or 1- or 3-week diets
12h light/dark cycle
Water ad libitum
Fasted 8-10 hours pre-diet
Ketogenic diet (78% F, 0.76% C)
or control (5% F, 65% C)
kcal restrict to 90% daily
requirements
7 day diet
2 groups: Ketogenic diet (n=20)
and control (n=20)
Food access 2.5 hours per day

NAD(P)H:quinone oxidoreductase
(NQO1) activity
4-hydroxy-2-nonenal (4-HNE)
Glutathione (GSH)
Reduced coenzyme A (CoASH)

Higher 3-HB concentrations were associated
with increases in neuronal oxidative
metabolism and metabolic rate Higher 3-HB
concentrations were associated with increased
ATP production, NAD/NADH ratio, and
mitochondrial electron transport chain activity
Higher 3-HB concentrations were associated
with increased BDNF mRNA and protein
expression in low glucose concentration areas
Ketogenic diet was associated with increased
hippocampal GSH synthesis and NQO1 activity
Ketogenic diet was associated with decreased
CoASH and GSH

Serum Β-HB
Porsolt Test: animal model of
depression

Ketogenic diet was associated with an increase
in serum Β-HB
Ketogenic diet was associated with better
performance on the Porsolt test, indicating less
behavioral despair
Ketogenic diet may have antidepressant
properties
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Table 1. Studies investigating the ketogenic diet and characteristics of MDD
Reference

Design

Participants

Intervention

Primary Outcome(s)

Results/conclusions
All groups experienced weight loss and lean
mass loss, but there was no difference between
groups
All groups experience fat mass loss, but the
VLC and VLF groups experienced greater
reductions
LDL and HDL were increased more in the VLC
group compared to the other groups
TGs were decreased in the VLC group
compared to other groups
Blood glucose did not change for any groups
Fasting insulin was decreased more in the VLC
group compared to the other groups
LCD was associated with greater weight loss
compared to the LFD
TGs were decreased more in the LCD diet
Neither experienced a significant change in
HDL or LDL
Glucose levels were only significantly
decreased in LCD participants who had
diabetes
Both groups experienced weight loss but there
was no difference between groups
Changes in total cholesterol and LDL were not
different between baseline and follow-up or
between groups
TGs decreased more in the LCD group
HDL decreased in both groups, but was reduced
more in the LFD group
Changes in blood glucose were not different
between baseline and follow-up or between
groups
HbA1c was lower for the LCD group only for
participants with diabetes
Ketogenic diet was associated with an increase
in serum Β-HB levels
Ketogenic diet was associated with an increase
in hippocampal mitochondrial respiration rate
Ketogenic diet was associated with decreased
ROS production in hippocampi

Noakes and
colleagues
(2006)60

RCT

67 adults
One or more
cardiovascular risk
factor BMI > 28 kg/m22

12-week diet: 8-week intervention
and 4-week weight maintenance
Isocaloric diet 1450kcal
Very Low Fat (VLF)
(Carbohydrate%: Fat%: Protein%,
%SF = 70:10:20; 3%)
High Unsaturated Fat (HUF) =
(50:30:20, 6%)
Very Low Carbohydrate (VLC)
(4:61:35, 20%)

Body Weight
Fat Mass
Lean Mass
Serum total cholesterol (TC)
Serum High density lipoprotein (HDL)
Serum Low density lipoprotein (LDL)
Serum Triglycerides (TGs)
Blood glucose
Fasting insulin

Samaha and
colleagues
(2003)55

RCT

132 adults
Severely obese (BMI >
35kg/m2)

6-month diet
Low carbohydrate diet (LCD): <
30 g CHO/day, no restriction on fat
intake
Low fat diet (LFD): 500 kcal
deficit, < 30% kcal from fat

Body weight
Serum Triglycerides (TGs)
Serum High density lipoprotein (HDL)
Serum Low density lipoprotein (LDL)
Fasting blood glucose

Stern and
colleagues
(2004)59

RCT

87 adults
Severely obese (BMI >
35kg/m2)

1-year follow-up
Low carbohydrate diet (LCD): <
30 g CHO/day, no restriction on fat
intake
Low fat diet (LFD): 500 kcal
deficit, < 30% kcal from fat

Body weight
Serum total cholesterol (TC)
Serum High density lipoprotein (HDL)
Serum Low density lipoprotein (LDL)
Serum Triglycerides (TGs)
Blood glucose
HbA1c

Sullivan and
colleagues
(2004)48

RCT

45 C3HeB/FeJ mice

10-12 day diet
Ketogenic diet (Bio-Serv F3666)
(n=22)
Standard diet (n=23)
Food and water ad libitum

Serum Β-HB
Hippocampal mitochondrial respiration
and Reactive Oxygen Species (ROS)
production
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Table 1. Studies investigating the ketogenic diet and characteristics of MDD
Reference

Design

Participants

Sussman and
colleagues
(2014)52

RCT

24 Male and female
CD-1 parental mice
44 6-weeks old
offspring mice

Tay and
colleagues
(2008)62

RCT

109 adults
Ages 18 to 65
Abdominal obesity and
one or more metabolic
syndrome risk factors

Vizuete and
colleagues
(2013)44

RCT

60 male Wistar rats, 30
days old

Yancy and
colleagues
(2004)54

RCT

119 overweight,
hyperlipidemic adults
Age 18-65 y
BMI 30-60 kg/m2

Intervention

Primary Outcome(s)

Results/conclusions

30-day diet for parent mice
KD (67.4% fat, 0.6% carbohydrate,
and 15.3% protein) or control (5%
fat, 76.1% carbohydrate, and
18.9% protein)
Ad libitum food and water
Males and female naturally mated
after diet ended
Ketogenic diet (n=20) and control
(n=24) offspring tested
24-week diet
Very Low Carbohydrate High Fat
diet (VLCHF; 4% carbohydrate,
35% protein, 61% fat)
High Carbohydrate Low Fat diet
(HCLF; 46% carbohydrate, 24%
protein, 30% fat (< 8% sat fat);
<10g/d saturated fat
Both diets restricted to 1430 kcal
for women and 1670 kcal for men

Open-field test (locomotor activity and
anxiety model)
Forced-swim test (behavioral despair
model)
Exercise-wheel test (physical activity
model)

Ketogenic diet was associated with reduced
susceptibility to depression and anxiety and
increased physical activity in offspring
Ketogenic diet was associated with an increase
in the volume of cerebellum and decreases in
the volumes of hypothalamus and corpus
callosum

Body weight
Serum total cholesterol (TC)
Serum High density lipoprotein (HDL)
Serum Low density lipoprotein (LDL)
Serum Triglycerides (TGs)
Blood glucose
C-reactive Protein (CRP)

8-week diet
3 groups: control (n=20), standard
ketogenic diet (n=20), enriched
omega-3 ketogenic diet (n=20)
12h light/dark cycle
Low Carbohydrate Ketogenic Diet
(LCKD, < 20 g carbohydrate) (n=
59)
Low Fat Diet (LFD, < 30% fat,
<300mg cholesterol, 100-500 kcal
restriction) (n=60)
45 LCKD and 34 LFD completed

BDNF concentration in hippocampi
and corpus striatum

Both diets resulted in weight loss, with no
differences between groups
Total cholesterol and LDL decreased in the
HCLF group, but did not change in the VLCHF
group
HDL increased in both groups, but was higher
in the VLCHF group
TGs decreased in both groups, but were
reduced more in the VLCHF group
Fasting glucose and CRP decreased in both
groups, but there were no differences between
groups
Ketogenic diet was associated with decreased
BDNF content in the corpus striatum and no
change in the hippocampi

Body weight
Triglycerides (TGs)
High density lipoprotein (HDL)
Low density lipoprotein (LDL)

LCKD was associated with a greater decrease
in body weight than the LFD
TGs were decreased more in the LCKD group
HDL was increased more in the LCKD group
LDL was increased in both groups, but was
higher in the LCKD group
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Table 1. Studies investigating the ketogenic diet and characteristics of MDD
Reference

Design

Participants

Yang and
colleagues
(2010)46

RCT

Male C57BL/6 J mice
8 weeks old

Zhang and
colleagues
(2013)40

RCT

19 male Wistar rats, 40
days old

Ziegler and
colleagues
(2003)50

RCT

20 Male Wistar rats,
30 days old

Intervention

Primary Outcome(s)

Results/conclusions

2-day or 1-week diet
Standard diet(SD) and water ad
libitum for 1-week pre-diet
Ketogenic diet or SD groups
With and without 1-methyl-4phenyl-1,2,3,6-tetrahydropyridine
(MPTP) injections (4 injections at
2-hour intervals)
Diets begin after injections
4-week diet: 1-week acclimation,
3-week intervention, ad libitum
feeding
Ketogenic diet (KD)
Standard diet (SD)

Dopamine concentrations
Proinflammatory cytokine levels
(Interleukin-1Beta, Interleukin-6,
Tumor Necrosis Factor-alpha)

Ketogenic diet protected dopaminergic neurons
against MPTP-induced degradation
KD inhibited increase of proinflammatory
cytokines produced by MPTP toxicity

Cerebral metabolic rate of glucose
(CMR-glu)
Blood glucose
Blood lactate
Blood ketones (Beta-hydroxybutyrate
and acetoacetate)

8-week diet
Ketogenic diet or standard
laboratory diet
Food and water ad libitum

Thiobarbituric Acid Reactive
Substances (TBARS) assay
Total Antioxidant Reactivity (TAR)
assay
Catalase(CAT) assay
Superoxide dismutase (SOD) assay
Glutathione peroxidase (GPx) assay

No differences in plasma glucose between
groups after feeding
Plasma ketones higher and plasma lactate were
lower in KD group than SD group
CMR-glu was decreased in left and right
cerebral hemispheres and cerebellum in KD
group
CMR-glu was lower in both hemispheres than
in the cerebellum
TBARS levels (lipoperoxidation) was increased
in cerebellum of ketogenic diet rats
TAR (antioxidant capacity) was increased in
hippocampus and decreased in cerebellum of
ketogenic diet rats
In hippocampus, CAT activity decreased ~50%
and GPx activity increased ~400% in ketogenic
diet rats
Ketogenic diet may have neuroprotective
qualities through increases in antioxidant
capacity in certain regions of the brain
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Appendix A
Recruitment Email
Subject: If You Are a Veteran, This Exciting Nutrition Study May Be For YOU!
Are you ready improve your overall health? Do you want a free nutrition consultation and a
personalized diet plan? Do you want free body composition testing and analysis? Do you want
free assessment of your blood glucose and a full lipid profile?
By participating in our study, you will have access to both a registered dietitian and fitness
professional and receive a comprehensive health and nutrition assessment during the course of the
study. Additionally, if you successfully complete the study, you may eligible to receive a new
FitBit Charge 2.
Our names are Dr. Jeremy Akers, RDN and Jordan Murrin and we are an Associate Professor and
Graduate Student research team here at James Madison University in the Health Professions
Department. We are conducting a research study on the effect of two dietary interventions on
body composition and metabolic health and are looking for veterans of United States Armed
Forces to participate. Details of the study can be found below. If you or a friend are interested in
participating, please contact Jordan Murrin via email or telephone.
Contact Information:
Name: Jordan Murrin, Graduate Student Researcher
Email: murrinja@dukes.jmu.edu
Phone: 703-565-3001
Name: Dr. Jeremy Akers, PhD, RDN
Email: akersjd@jmu.edu
Phone: 540-568-8974
Who: Any veteran of the United States Armed Forces between the ages of 18-65 years.
What: Participation includes: 12 weeks of FREE nutrition consultation; FREE tests to measure
body fat and composition, blood glucose, and full lipid profiles; and a FREE personalized diet
plan and dietary analysis.
When: February 2020
Thank you,
Dr. Jeremy Akers and Jordan Murrin
* Approved by the James Madison University Institutional Review Board, Protocol No. 20-1039
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Sample Recruitment Flyer
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Appendix B
Questionnaires
Health Status Questionnaire
1. Has anyone in your family had a heart attack, heart surgery, or sudden death due to
cardiovascular disease prior to the age of 65? (Circle one)
Yes
No
If yes, who?
______________________________________________________________________________
How old were they? (Circle one)
54 or younger 55-59
60-64
2. Date of last medical exam: _______________________
3. Please list any operations that you have had:
______________________________________________________________________________

4. Please list any physical or mental health conditions for which you have been diagnosed or are
being treated for by a physician or health professional:

5. Please answer the questions below related to medication use:
•
•

If yes, please fill in the medication name.
Indicate whether you have taken the medication for the given amount of time without any
changes to medication type or dosage.

Do you currently take any medications for any of the following conditions?
Depression? ______________________ Have you taken this for ≥ 8 weeks? __________
Anxiety? ______________________ Have you taken this for ≥ 8 weeks?___________
Diabetes? ________________________ Have you taken this for ≥ 2 weeks? ________
High cholesterol? _____________________ Have you taken this for ≥ 8 weeks? ______
High blood pressure? __________________ Have you taken this for ≥ 2 weeks? ______
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Please list all medications taken in the last six months and how long you have been taking them.

6. The occurrence of any of these health symptoms frequently is the basis for medical attention.
Please check how often you have each of the following:
Symptom

1
Rarely

2
Infrequently

3
Sometimes

4
Fairly Often

5
Very Often

Cough up blood
Abdominal pain
Low back pain
Leg pain
Arm or shoulder
pain
Chest pain
Swollen joints
Feel faint
Dizziness
Breathless on
slight exertion

7. Have you ever been diagnosed with any psychological disorders other than major

depressive disorder or an anxiety disorder?
__________________
If yes, please explain.
______________________________________________________
8. Have you ever or do you currently use mood stabilizers or antipsychotics medications?
__________________
If yes, please explain. _______________________________________________

57
9. Have you experienced any weight loss or weight gain >10lbs (4.5 kg) in the past 6

months?
__________________
If yes, please explain.
______________________________________________________
10. Have you followed of a low carbohydrate diet in the past 3 months?
___________________
If yes, please explain.
______________________________________________________
11. Do you smoke? (Circle one)

Yes

No

If yes, how many per day:
Cigarettes:

1-9

10-19

Cigars or pipes only:

5 or more or any inhaled

20-39

40 or

more
less than 5, none inhaled

Adapted from: Howley and Franks. (1992). Health Fitness Instructor’s Handbook. Health Status
Questionnaire. Champaign: Human Kinetics.
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Beck's Depression Inventory-II (BDI-II)
Please circle the answer that most accurately applies to any symptoms that you experience.
1.
0
1
2
3

I do not feel sad.
I feel sad
I am sad all the time and I can't snap out of it.
I am so sad and unhappy that I can't stand it.

0
1
2
3

I am not particularly discouraged about the future.
I feel discouraged about the future.
I feel I have nothing to look forward to.
I feel the future is hopeless and that things cannot improve.

0
1
2
3

I do not feel like a failure.
I feel I have failed more than the average person.
As I look back on my life, all I can see is a lot of failures.
I feel I am a complete failure as a person.

0
1
2
3

I get as much satisfaction out of things as I used to.
I don't enjoy things the way I used to.
I don't get real satisfaction out of anything anymore.
I am dissatisfied or bored with everything.

0
1
2
3

I don't feel particularly guilty
I feel guilty a good part of the time.
I feel quite guilty most of the time.
I feel guilty all of the time.

0
1
2
3

I don't feel I am being punished.
I feel I may be punished.
I expect to be punished.
I feel I am being punished.

0
1
2
3

I don't feel disappointed in myself.
I am disappointed in myself.
I am disgusted with myself.
I hate myself.

0
1
2
3

I don't feel I am any worse than anybody else.
I am critical of myself for my weaknesses or mistakes.
I blame myself all the time for my faults.
I blame myself for everything bad that happens.

0
1
2
3

I don't have any thoughts of killing myself.
I have thoughts of killing myself, but I would not carry them out.
I would like to kill myself.
I would kill myself if I had the chance.

2.

3.

4.

5.

6.

7.

8.

9.
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10.
0
1
2
3

I don't cry any more than usual.
I cry more now than I used to.
I cry all the time now.
I used to be able to cry, but now I can't cry even though I want to.

0
1
2
3

I am no more irritated by things than I ever was.
I am slightly more irritated now than usual.
I am quite annoyed or irritated a good deal of the time.
I feel irritated all the time.

0
1
2
3

I have not lost interest in other people.
I am less interested in other people than I used to be.
I have lost most of my interest in other people.
I have lost all of my interest in other people.

0
1
2
3

I make decisions about as well as I ever could.
I put off making decisions more than I used to.
I have greater difficulty in making decisions more than I used to.
I can't make decisions at all anymore.

0
1
2
3

I don't feel that I look any worse than I used to.
I am worried that I am looking old or unattractive.
I feel there are permanent changes in my appearance that make me look
unattractive
I believe that I look ugly.

0
1
2
3

I can work about as well as before.
It takes an extra effort to get started at doing something.
I have to push myself very hard to do anything.
I can't do any work at all.

0
1
2
3

I can sleep as well as usual.
I don't sleep as well as I used to.
I wake up 1-2 hours earlier than usual and find it hard to get back to sleep.
I wake up several hours earlier than I used to and cannot get back to sleep.

0
1
2
3

I don't get more tired than usual.
I get tired more easily than I used to.
I get tired from doing almost anything.
I am too tired to do anything.

0
1
2
3

My appetite is no worse than usual.
My appetite is not as good as it used to be.
My appetite is much worse now.
I have no appetite at all anymore.

0
1
2
3

I haven't lost much weight, if any, lately.
I have lost more than five pounds.
I have lost more than ten pounds.
I have lost more than fifteen pounds.

11.

12.

13.

14.

15.

16.

17.

18.

19.
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20.
0
1
2
3

I am no more worried about my health than usual.
I am worried about physical problems like aches, pains, upset stomach, or
constipation.
I am very worried about physical problems and it's hard to think of much else.
I am so worried about my physical problems that I cannot think of anything else.

0
1
2
3

I have not noticed any recent change in my interest in sex.
I am less interested in sex than I used to be.
I have almost no interest in sex.
I have lost interest in sex completely.

21.

INTERPRETING THE BECK DEPRESSION INVENTORY (For researcher use only)
Now that you have completed the questionnaire, add up the score for each of the twenty-one
questions by counting the number to the right of each question you marked. The highest possible
total for the whole test would be sixty-three. This would mean you circled number three on all
twenty-one questions. Since the lowest possible score for each question is zero, the lowest
possible
score for the test would be zero. This would mean you circles zero on each question.
You can evaluate your depression according to the Table below.
Total Score ____________________

Levels of Depression

1-10

These ups and downs are considered normal

____________________

11-16 ____________________

Mild mood disturbance

17-20 ____________________

Borderline clinical depression

21-30 ____________________

Moderate depression

31-40 ____________________

Severe depression

> 40

Extreme depression

____________________

Adapted from: Beck A, Steer R, Brown G. Manual for the beck depression inventory-II. 1996.
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Beck Anxiety Inventory
Below is a list of common symptoms of anxiety. Please carefully read each item in the list.
Indicate how much you have been bothered by that symptom during the past month, including
today, by circling the number in the corresponding space in the column next to each symptom.

Not at
All

Mildly – but it
didn’t bother
me much.

Moderately - it
wasn’t pleasant
at times

Severely – it
bothered me a
lot

Numbness or tingling

0

1

2

3

Feeling hot

0

1

2

3

Wobbliness in legs

0

1

2

3

Unable to relax

0

1

2

3

Fear of worst
happening

0

1

2

3

Dizzy or lightheaded

0

1

2

3

Heart pounding/racing

0

1

2

3

Unsteady

0

1

2

3

Terrified or afraid

0

1

2

3

Nervous

0

1

2

3

Feeling of choking

0

1

2

3

Hands trembling

0

1

2

3

Shaky/unsteady

0

1

2

3

Fear of losing control

0

1

2

3

Difficulty in breathing

0

1

2

3

Fear of dying

0

1

2

3

Scared

0

1

2

3

Indigestion

0

1

2

3

Faint/lightheaded

0

1

2

3

Face flushed

0

1

2

3

Hot/cold sweats

0

1

2

3
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For researcher use only

Column Sum
Scoring - Sum each column. Then sum the column totals to achieve a total score. Write that score
below.
Total Sum ______________________
Interpretation
A grand sum between 0 – 21 indicates very low anxiety. That is usually a good thing. However, it
is possible that you might be unrealistic in either your assessment which would be denial or that
you have learned to “mask” the symptoms commonly associated with anxiety. Too little
“anxiety” could indicate that you are detached from yourself, others, or your environment.
A grand sum between 22 – 35 indicates moderate anxiety. Your body is trying to tell you
something. Look for patterns as to when and why you experience the symptoms described above.
For example, if it occurs prior to public speaking and your job requires a lot of presentations you
may want to find ways to calm yourself before speaking or let others do some of the
presentations. You may have some conflict issues that need to be resolved. Clearly, it is not
“panic” time, but you want to find ways to manage the stress you feel.
A grand sum that exceeds 36 is a potential cause for concern. Again, look for patterns or times
when you tend to feel the symptoms you have circled. Persistent and high anxiety is not a sign of
personal weakness or failure. It is, however, something that needs to be proactively treated or
there could be significant impacts to you mentally and physically. You may want to consult a
counselor if the feelings persist.

Adapted from: Beck AT, Epstein N, Brown G, Steer RA. An inventory for measuring clinical
anxiety. Journal of Consulting and Clinical Psychology. 1988;56(6):893-897.
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INTERNATIONAL PHYSICAL ACTIVITY QUESTIONNAIRE
We are interested in finding out about the kinds of physical activities that people do as part of
their everyday lives. The questions will ask you about the time you spent being physically active
in the last 7 days. Please answer each question even if you do not consider yourself to be an
active person. Please think about the activities you do at work, as part of your house and yard
work, to get from place to place, and in your spare time for recreation, exercise or sport.
Think about all the vigorous and moderate activities that you did in the last 7 days. Vigorous
physical activities refer to activities that take hard physical effort and make you breathe much
harder than normal. Moderate activities refer to activities that take moderate physical effort and
make you breathe somewhat harder than normal.

PART 1: JOB-RELATED PHYSICAL ACTIVITY
The first section is about your work. This includes paid jobs, farming, volunteer work, course
work, and any other unpaid work that you did outside your home. Do not include unpaid work
you might do around your home, like housework, yard work, general maintenance, and caring for
your family. These are asked in Part 3.
1.

Do you currently have a job or do any unpaid work outside your home?

Yes
No

Skip to PART 2: TRANSPORTATION

The next questions are about all the physical activity you did in the last 7 days as part of your
paid or unpaid work. This does not include traveling to and from work.
2.

During the last 7 days, on how many days did you do vigorous physical activities like
heavy lifting, digging, heavy construction, or climbing up stairs as part of your work?
Think about only those physical activities that you did for at least 10 minutes at a time.
_____ days per week
No vigorous job-related physical activity

3.

Skip to question 4

How much time did you usually spend on one of those days doing vigorous physical
activities as part of your work?
_____ hours per day
_____ minutes per day
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4.

Again, think about only those physical activities that you did for at least 10 minutes at a
time. During the last 7 days, on how many days did you do moderate physical activities
like carrying light loads as part of your work? Please do not include walking.
_____ days per week
No moderate job-related physical activity
question 6

5.

Skip to

How much time did you usually spend on one of those days doing moderate physical
activities as part of your work?
_____ hours per day
_____ minutes per day

6.

During the last 7 days, on how many days did you walk for at least 10 minutes at a time
as part of your work? Please do not count any walking you did to travel to or from
work.
_____ days per week
No job-related walking

7.

Skip to PART 2: TRANSPORTATION

How much time did you usually spend on one of those days walking as part of your
work?
_____ hours per day
_____ minutes per day

PART 2: TRANSPORTATION PHYSICAL ACTIVITY
These questions are about how you traveled from place to place, including to places like work,
stores, movies, and so on.
8.

During the last 7 days, on how many days did you travel in a motor vehicle like a train,
bus, car, or tram?
_____ days per week
No traveling in a motor vehicle

9.

Skip to question 10

How much time did you usually spend on one of those days traveling in a train, bus, car,
tram, or other kind of motor vehicle?
_____ hours per day
_____ minutes per day
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Now think only about the bicycling and walking you might have done to travel to and from
work, to do errands, or to go from place to place.
10.

During the last 7 days, on how many days did you bicycle for at least 10 minutes at a
time to go from place to place?
_____ days per week
No bicycling from place to place

Skip to question 12

11.
How much time did you usually spend on one of those days to bicycle from place to
place?
_____ hours per day
_____ minutes per day
12.

During the last 7 days, on how many days did you walk for at least 10 minutes at a time
to go from place to place?
_____ days per week
No walking from place to place

13.

Skip to PART 3:
HOUSEWORK, HOUSE
MAINTENANCE, AND
CARING FOR FAMILY

How much time did you usually spend on one of those days walking from place to place?
_____ hours per day
_____ minutes per day

PART 3: HOUSEWORK, HOUSE MAINTENANCE, AND CARING FOR FAMILY
This section is about some of the physical activities you might have done in the last 7 days in and
around your home, like housework, gardening, yard work, general maintenance work, and caring
for your family.
14.

Think about only those physical activities that you did for at least 10 minutes at a time.
During the last 7 days, on how many days did you do vigorous physical activities like
heavy lifting, chopping wood, shoveling snow, or digging in the garden or yard?
_____ days per week
No vigorous activity in garden or yard

Skip to question 16
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15.

16.

How much time did you usually spend on one of those days doing vigorous physical
activities in the garden or yard?
_____ hours per day
_____ minutes per day
Again, think about only those physical activities that you did for at least 10 minutes at a
time. During the last 7 days, on how many days did you do moderate activities like
carrying light loads, sweeping, washing windows, and raking in the garden or yard?
_____ days per week
No moderate activity in garden or yard

17.

Skip to question 18

How much time did you usually spend on one of those days doing moderate physical
activities in the garden or yard?
_____ hours per day
_____ minutes per day

18.

Once again, think about only those physical activities that you did for at least 10 minutes
at a time. During the last 7 days, on how many days did you do moderate activities like
carrying light loads, washing windows, scrubbing floors and sweeping inside your
home?
_____ days per week
No moderate activity inside home

19.

Skip to PART 4:
RECREATION, SPORT
AND LEISURE-TIME
PHYSICAL ACTIVITY

How much time did you usually spend on one of those days doing moderate physical
activities inside your home?
_____ hours per day
_____ minutes per day

PART 4: RECREATION, SPORT, AND LEISURE-TIME PHYSICAL ACTIVITY
This section is about all the physical activities that you did in the last 7 days solely for recreation,
sport, exercise or leisure. Please do not include any activities you have already mentioned.
20.

Not counting any walking you have already mentioned, during the last 7 days, on how
many days did you walk for at least 10 minutes at a time in your leisure time?
_____ days per week
No walking in leisure time

Skip to question 22
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21.

How much time did you usually spend on one of those days walking in your leisure
time?
_____ hours per day

22.

_____ minutes per day

Think about only those physical activities that you did for at least 10 minutes at a time.
During the last 7 days, on how many days did you do vigorous physical activities like
aerobics, running, fast bicycling, or fast swimming in your leisure time?
_____ days per week
No vigorous activity in leisure time

23.

How much time did you usually spend on one of those days doing vigorous physical
activities in your leisure time?
_____ hours per day

24.

Skip to question 24

_____ minutes per day

Again, think about only those physical activities that you did for at least 10 minutes at a
time. During the last 7 days, on how many days did you do moderate physical activities
like bicycling at a regular pace, swimming at a regular pace, and doubles tennis in your
leisure time?
_____ days per week
No moderate activity in leisure time

25.

Skip to PART 5: TIME
SPENT SITTING

How much time did you usually spend on one of those days doing moderate physical
activities in your leisure time?
_____ hours per day
_____ minutes per day

PART 5: TIME SPENT SITTING
The last questions are about the time you spend sitting while at work, at home, while doing
course work and during leisure time. This may include time spent sitting at a desk, visiting
friends, reading or sitting or lying down to watch television. Do not include any time spent sitting
in a motor vehicle that you have already told me about.
26.

During the last 7 days, how much time did you usually spend sitting on a weekday?
_____ hours per day

27.

_____ minutes per day

During the last 7 days, how much time did you usually spend sitting on a weekend day?
_____ hours per day

_____ minutes per day

Adapted from: Booth M. Assessment of physical activity: An International perspective. Research
Quarterly for Exercise and Sport. 2000;71:114–120.
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Appendix C
Ketogenic Diet Handout
Participant ID #: ________________
Welcome to our research study and thank you for your participation! If you have any questions
or concerns at any time during your participation, please contact our research team.
Graduate Student Researcher
Jordan Murrin
murrinja@dukes.jmu.edu
703-565-3001

Research Supervisor
Jeremy Akers, PhD, RDN
akersjd@jmu.edu
540-568-8974

Appendix A – Ketogenic Diet
The ketogenic diet is a dietary plan that is high in fat and very low in carbohydrates, while
maintaining adequate protein intake. It requires a restriction of carbohydrate intake to achieve
“ketosis”, which mimics a fasted state and forces the body to utilize fats from your diet and those
stored in your body for fuel. As these fats are broken down for energy, they are turned into
ketones, which replace most of your body’s carbohydrates as a major source for energy.
To benefit from the ketogenic diet, it is important to eat foods that are low in carbohydrates and
to eat the appropriate number of calories to achieve and maintain a healthy weight. The diet
typically includes plenty of fatty fish, meats, eggs, nuts, seeds, vegetable-based oils, and fibrous
vegetables.
This handout is meant to provide you with recommendations that you may use to maintain the
ketogenic diet. The main goal for the ketogenic diet is to achieve ketosis by restricting your total
carbohydrate intake to less than 50 grams of carbohydrates per day. You can accomplish this
by reading nutrition labels on food, planning your meals, and even using the provided resources
to make “keto-friendly” recipes.
The tables on the next page outlines the main food groups and provides instructions for making
food choices that are higher in fat and lower in carbohydrate. An emphasis on foods high
in saturated fat is not recommended by the Dietary Guidelines for Americans and the American
Heart Association and may have adverse effects on blood LDL cholesterol. Therefore, for this
diet, you should emphasize high-total fat foods that are also lower in saturated fat such as fatty
fish, avocado, nuts, seeds, and vegetable-based oils (includes canola, corn, olive, peanut,
safflower, sesame, soybean, and sunflower oils).
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Approximate Daily Calorie Needs for Men

Age (years)

19–30
31–50
51+

Calories Needed
for Sedentary
Activity Level
2,400 – 2,600
2,200-2,400
2,000-2,200

Calories Needed
for Moderately
Active Activity
Level
2,600–2,800
2,400–2,600
2,200–2,400

Calories Needed
for Active Activity
Level
3,000
2,800–3,000
2,400–2,800

Approximate Daily Calorie Needs for Women

Age (years)

19–30
31–50
51+

Calories Needed
for Sedentary
Activity Level
1,800-2,000
1,800
1,600

Calories Needed
for Moderately
Active Activity
Level
2,000-2,200
2,000
1,800

Calories Needed
for Active Activity
Level
2,400
2,200
2,200

Tips for Eating Out on Keto
•

•

•
•

•

Avoid starches
o Ask for your food to be served without bread, pasta, potatoes, or rice
o Be wary of starchy vegetables like potatoes (all types/forms), corn, peas,
beets, carrots, or onions
o See the “Low Carbohydrate Foods and Foods to Avoid” handout to
determine what foods should be avoided
Add healthy fat
o Ask for extra butter for veggies or meat
o Use olive oil and vinegar dressing
o Use heavy cream or coconut milk in your coffee or tea
Watch out for sauces and condiments
o Some contain mostly fat, but others have added sugars
Choose the appropriate drink
o Plain water, sparkling water (no sugar added), tea, or coffee are great
options
o Avoid sugar-sweetened beverages, juices, and alcohol
Rethink dessert
o Most dessert are not only high in fat, but added sugars too
o Drink (decaf) coffee or tea with cream or coconut milk instead
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Appendix B - Low Carbohydrate Foods and Foods to Avoid
This handout is meant to give you a better idea of what foods to choose in order to maintain your
low-carbohydrate diet. It will give you general DOs and DON’Ts in terms of food choices so that
you have a general idea of some low-carb and high-carb foods. The first column will consist of
your low-carb foods, while the “avoid” column will consist of high-carb foods that you will want
to avoid and eliminate from your diet. Keep in mind that this list is not exhaustive and there other
low-carb foods that are not on this list.
Experimenting and combining low-carb foods in different ways will keep your diet from
becoming monotonous. Meal prepping in advance may be beneficial if you have limited time
during the week to cook meals so that you always have food ready to eat. Having meals and
snacks ready in advance may also prevent any temptation or impulse to eat high-carb foods that
are not permitted while following this regiment.
It is important to pay attention to what you eat because some of these foods do contain
carbohydrates. If you over-consume a particular food, you may easily go over your daily 50 g
CHO limit. Yogurt and cottage cheese especially should be consumed in moderation.

Zero/Low CHO foods
Meats, Fish, &
Alternatives

Dairy
Products &
Alternatives

Oils, Fats, &
Nuts/Seeds

Steak
Ground hamburger
Bacon*
Sausage*
Pork
Ham*
Salmon
Cod
Flounder
Lamb
Tofu*
Prepackaged lunch
meats
Cottage cheese (1/2 c)
Brie (1 oz)
Camembert (1 oz)
Blue cheese (1 oz)
Cheddar (1 oz)
Sheep and goat cheeses
(1 oz)
Mozzarella (1 oz)
Peanut butter (no added
sugar)
Almond butter (no
added sugar)

Avoid

Chicken (skin on)
Eggs
Veal
Venison
Duck
Tuna*
Shellfish
Tilapia
Shrimp
Lobster
(all un-breaded meat)

Any breaded meats or fish
Look for additives in canned
tuna
Tempeh
Seitan

Whole milk (<1c/day)
High-fat yogurts (plain
only)
Cream (40% fat or more)
Sour cream
Almond milk
(unsweetened)
Coconut milk
(unsweetened)
Feta (1 oz)
Butter
Canola oil
Vegetable oil
Almonds
Shortening

Ice cream
Yogurts with added fruit
Low fat dairy
Milk

Margarine
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Sunflower butter (no
added sugar)
Olive oil
Coconut oil
Mayonnaise*

Vegetables

Cabbage
Broccoli
Brussel sprouts
Kale
Spinach
Celery
Bok choy
Bell pepper
Alfalfa sprouts
Chives
Endive
Fennel
Radicchio
Artichoke hearts

Fruits
Grains
Herbs/Spices

Sesame oil
Sunflower seeds
Pine nuts
Peanuts
Walnuts
Macadamia nuts
Pumpkin seeds
Pecans
Avocado (1/2 whole)
Eggplant
Asparagus
Zucchini
Cucumber
Swiss chard
Tomatoes
Radishes
Chicory greens
Daikon
Mushrooms
Iceberg/Romaine
Olives

No fruit allowed
No grains allowed
Basil
Dill
Garlic
Oregano
Rosemary
Tarragon
Cinnamon
Nutmeg
Paprika

Cayenne pepper
Cilantro
Ginger
Pepper
Sage
Turmeric
Curry
Thyme
Salt

Potatoes (all types/forms)
Corn
Peas
Parsnips
Plantains
Beets
Carrots
Onions

Avoid all fruit
Avoid all breads, pastas,
wheat, spelt, rye, barley,
cereals
Spice mixtures may contain
added sugar
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Salad
Dressings

Balsamic vinegar
Caesar (2 tbs)
Italian (2 tbs)

Oil and vinegar (2 tbs)
Blue cheese (2 tbs)
Ranch (2 tbs)

Beverages

Clear broth*
Flavored seltzer*
Water

Carbonated water
Decaf coffee or tea
Diet soda

Other

Mustard*
Soy sauce
Horseradish
Salsa*
Pesto*
Cider/wine vinegars
Teriyaki sauce
*Check all labels for added sugars or fillers that may add carbs

No dressings with added
sugar and no more than 2
grams of net carbs per
serving
Beer/wine/liquor**
Gatorade
Endurance/energy drinks
Regular soda
Fruit beverages
Chocolate milk
Artificial sweeteners
Jams, jellies, preserves
Chips, pretzels
Cookies, cakes, candy
Ketchup, Tartar sauce
Steak sauce
Barbeque sauce

**Alcoholic beverages should be minimized, as alcohol reduces
ketosis**
However, there are some low carbohydrate beers available, such as
Michelob Ultra (2.6g carbs), Corona Premier (2.6g carbs), and Miller Lite (3.2g
carbs).

*DO NOT UTILIZE ANY EXOGENOUS KETO
SUPPLEMENTS*
Includes ketone salts, ketone esters, and β-hydroxybutyrate (βHB)
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Appendix C - Sample Menus
Sample Menu 1
Breakfast (534 kcal, 6g carbs)
Omelet
3 eggs
1.5 tbsp of butter
¼ cup cheddar cheese
½ avocado
Snack (149 kcal, 12g carbs)
8 ounces of whole milk
Lunch (657 kcal, 1g carbs)
6 oz 80% lean hamburger patty, no bun
1 slice of provolone cheese
2 medium slices of bacon
Snack (204 kcal, 11g carbs)
1 cup of celery
2 tbsp. of peanut butter
Dinner (662 kcal, 6g carbs)
6-ounce chicken leg quarter, skin eaten
1 cup of broccoli
2 tbsp. of canola oil
Totals: 2,206 kcal, 36g carbs, 6.5% carbs

214 kcal, 1g carbs
152 kcal
114 kcal
109 kcal, 5g carbs

149kcal, 12g carbs

470kcal
100kcal, 1g carbs
87kcal

16 kcal, 3g carbs
188kcal, 8g carbs

392kcal
30kcal, 6g carbs
240kcal
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Sample Menu 2
Breakfast (379 kcal, 12g carbs)
2 medium slices of bacon
2 large hard-boiled eggs
8 ounces full fat plain yogurt

87 kcal
154kcal, 1g carbs
138kcal, 11g carbs

Snack (171 kcal, 2g carbs)
2 ounces of mozzarella cheese (2 slices or 2 cheese sticks)

171kcal, 2g carbs

Lunch (611 kcal, 7g carbs)
6-ounce pork chop
1 cup of cottage cheese

405kcal
206kcal, 7g carbs

Snack (321 kcal, 17g carbs)
8 ounces of whole milk
1 ounce of almonds (22 almonds)

149kcal, 12g carbs
172kcal, 5g carbs

Dinner (756 kcal, 4g carbs)
6-ounce steak, fat eaten
2 cups of raw spinach
¼ cup of feta cheese
2 tbsp. of olive oil

Totals: 2,238 kcal, 42g carbs, 7.5% carbs

404kcal
14kcal, 2g carbs
99 kcal, 2g carbs
239kcal
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Appendix D - Meal Planning Resources
Recipe Resources

1. https://www.dietdoctor.com/low-carb/keto/recipes
2. https://www.tasteofhome.com/collection/keto-diet-recipes/view-all/
3. https://www.delish.com/keto-recipes/
4. https://www.allrecipes.com/recipes/22959/healthy-recipes/keto-diet/
5. https://www.ditchthecarbs.com/recipes/
Sample Recipes
Breakfast

1) Baked Eggs with Coconut Milk and Cilantro
a) Ingredients
i) Virgin coconut or vegetable oil (for ramekins)
ii) 2 large eggs
iii) 2 tablespoons unsweetened coconut milk
iv) Kosher salt
v) ½ cup cilantro leaves with tender stems
vi) 1 teaspoon fresh lime juice
vii) 1 teaspoon green hot sauce
viii) Store-bought fried shallots (for serving)
b) Instructions
i) Preheat oven to 300°. Coat 2 small ramekins or other ovenproof dishes with
oil. Add 1 large egg and 1 Tbsp. coconut milk to each. Set on a rimmed
baking sheet and bake until eggs are barely set, 11–14 minutes; season with
salt.
ii) Toss cilantro in a small bowl with lime juice and hot sauce; season with salt.
Top eggs with cilantro mixture and shallots.
2) Keto Pancakes
a) Ingredients
i) 2 cups almond flour
ii) 8 tbsp butter, melted
iii) 1 tbsp avocado oil (or coconut)
iv) 1/4 cup water
v) 4 eggs
vi) 1 tsp vanilla extract
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vii) 1 tsp baking powder
viii) 2 tbsp sweetener of choice
ix) pinch of salt
x) extra butter for griddle
b) Instructions
i) Combine all ingredients in blender or food processor. Let mix until fully
combined. Let batter rest 5 minutes before cooking.
ii) Set a griddle (or nonstick skillet) to MED LOW heat. Use a 1/3 cup measuring
cup to portion out pancake batter.
iii) Cook until edges are firming up. The pancakes will not bubble up like
traditional ones but there will be little bubbles.
iv) Flip and cook 1 additional minute.
v) Serve hot with a pat of butter and sugar free maple syrup
3) Frittata with spinach
a) Ingredients
i) 5 oz. diced bacon or chorizo
ii) 2 tbsp butter
iii) 8 oz. fresh spinach
iv) 8 eggs
v) 1 cup heavy whipping cream
vi) 5 oz. shredded cheese
vii) salt and pepper
b) Instructions
i) Preheat the oven to 350°F (175°C). Grease a 9x9 baking dish or individual
ramekins.
ii) Fry the bacon in butter on medium heat until crispy. Add the spinach and stir
until wilted. Remove the pan from the heat and set aside.
iii) Whisk the eggs and cream together and pour into baking dish or in ramekins.
iv) Add the bacon, spinach and cheese on top and place in the middle of the oven.
Bake for 25–30 minutes or until set in the middle and golden brown on top.
Lunch/Dinner

1) Keto Chicken Enchilada Bowl
a) Ingredients
i) 2 tablespoons coconut oil (for searing chicken)
ii) 1 pound of boneless, skinless chicken thighs
iii) 3/4 cup red enchilada sauce
iv) 1/4 cup water
v) 1/4 cup chopped onion
vi) 1– 4 oz can diced green chilis
vii) toppings (feel free to customize)
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(1) 1 whole avocado, diced
(2) 1 cup shredded cheese (I used mild cheddar)
(3) 1/4 cup chopped pickled jalapenos
(4) 1/2 cup sour cream
(5) 1 roma tomato, chopped
viii) Optional: serve over plain cauliflower rice for a more complete meal!
b) Instructions
i) In a pot or dutch oven over medium heat melt the coconut oil. Once hot, sear
chicken thighs until lightly brown.
ii) Pour in enchilada sauce and water then add onion and green chilis. Reduce
heat to a simmer and cover. Cook chicken for 17-25 minutes or until chicken
is tender and fully cooked through to at least 165 degrees internal temperature.
iii) Carefully remove the chicken and place onto a work surface. Chop or shred
chicken (your preference) then add it back into the pot. Let the chicken
simmer uncovered for an additional 10 minutes to absorb flavor and allow the
sauce to reduce a little.
iv) To Serve, top with avocado, cheese, jalapeno, sour cream, tomato, and any
other desired toppings. Feel free to customize these to your preference. Serve
alone or over cauliflower rice if desired just be sure to update your personal
nutrition info as needed.
2) Lemon Butter Fish
a) Ingredients
i) LEMON BUTTER SAUCE:
(1) 60 g / 4 tbsp unsalted butter, cut into pieces
(2) 1 tbsp fresh lemon juice
(3) Salt and finely ground pepper
ii) CRISPY PAN-FRIED FISH:
(1) 2 x thin white fish fillets (120-150g / 4-5oz each), skinless boneless (I
used Bream, Note 1)
(2) Salt and pepper
(3) 2 tbsp white flour
(4) 2 tbsp oil
iii) SERVING:
(1) Lemon wedges
(2) Finely chopped parsley, optional
b) Instructions
i) LEMON BUTTER SAUCE:
(1) Place the butter in a light-colored saucepan or small skillet over medium
heat.
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(2) Melt butter then leave on the stove, whisking / stirring every now and
then. When the butter turns golden brown and it smells nutty - about 3
minutes, remove from stove immediately and pour into small bowl. (Note
2)
(3) Add lemon juice and a pinch of salt and pepper. Stir then taste when it has
cooled slightly. Adjust lemon/salt to taste.
(4) Set aside - it will stay pourable for 20 - 30 minutes. See Note 3 for storing.
ii) CRISPY PAN-FRIED FISH:
(1) Pat fish dry using paper towels. Sprinkle with salt & pepper, then flour.
Use fingers to spread flour. Turn and repeat. Shake excess flour off well,
slapping between hands if necessary.
(2) Heat oil in a non-stick skillet over high heat. When the oil is shimmering
and there are faint wisps of smoke, add fish. Cook for 1 1/2 minutes until
golden and crispy on the edges, then turn and cook the other side for 1 1/2
minutes (cook longer if you have thicker fillets).
(3) Remove immediately onto serving plates. Drizzle each with about 1 tbsp
of Sauce (avoid dark specks settled at the bottom of the bowl), garnish
with parsley and serve with lemon on the side.
3) Caveman Chili
a) Ingredients
i) 2 pounds ground pork
ii) 8 thick slices bacon, chopped
iii) 1 (14.5 ounce) can diced tomatoes, drained
iv) 1 onion, chopped
v) 3 small green bell peppers, chopped
vi) 1 (6 ounce) can tomato paste
vii) 1 (1.25 ounce) package chili seasoning (such as McCormick®)
viii) 1 pinch garlic powder, or more to taste
ix) 1 pinch onion powder, or more to taste
x) salt and ground black pepper to taste
xi) 1 pinch ground cayenne pepper, or more to taste
b) Instructions
i) Place pork in a skillet over medium heat; season with salt and pepper. Cook
and stir until browned and crumbly, 5 to 7 minutes. Drain and discard grease.
Transfer pork to a slow cooker.
ii) Place bacon in the hot skillet and cook over medium-high heat until evenly
browned, about 10 minutes. Drain and discard grease. Transfer bacon to the
slow cooker.
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iii) Combine drained tomatoes, onion, green bell pepper, and tomato paste into
the slow cooker. Add seasoning packet, garlic powder, onion powder, and salt,
pepper, cayenne pepper; stir to combine.
iv) Cook on Low until flavors have combined, about 6 hours.
Snacks
1) Bacon Blue Cheese Deviled Eggs
a) Ingredients
i) 8 hard-boiled eggs
ii) ¼ cup sour cream
iii) 1/3 cup mayonnaise
iv) 1 Tablespoon Dijon mustard
v) ½ teaspoon kosher salt
vi) ¼ teaspoon pepper
vii) ¼ teaspoon dill
viii) ¼ cup crumbled blue cheese
ix) 3 slices of cooked bacon chopped fine
x) Parsley for garnish
b) Instructions
i) To boil the perfect egg, simply place raw eggs in cold water and bring to a
boil. Once your reach a boil, set a timer for 10 minutes. When time is up,
drain and rinse the eggs in cold water and peel as soon as they are cool enough
to handle.
ii) Cut each hard-boiled egg in half and place the cooked yolk into a bowl and
the cooked egg white onto an egg plate.
iii) With a fork, mash the egg yolks until they resemble coarse crumbs. Add in the
sour cream, mayo, mustard and salt and pepper and mix very well until the
mixture is creamy (you could do this in a food processor if you wanted). Stir
in the remaining ingredients and taste the filling for seasoning. If the filling
seems a little dry, add in a spoonful more mayo
2) Keto Fat Bombs
a) Ingredients
i) 2 tablespoons coconut oil
ii) 2 tablespoons cocoa powder unsweetened
iii) 1/2 cup natural peanut butter
iv) 1/4 cup chia seeds
v) 1 teaspoon vanilla essence
vi) 2 tablespoons xylitol (or your preferred sweetener)
vii) 1/3 cup unsweetened shredded coconut
b) Instructions
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i) Melt Coconut Oil
ii) Put all ingredients "except melted coconut oil and shredded coconut" into a
bowl and mix well.
iii) Add melted coconut oil and mix until combined. Place the mixture in the
fridge for 30 minutes to allow the chia seeds to soak up the excess liquid and
the coconut oil to set.
iv) Spread shredded coconut out onto a flat dinner plate or tray.
v) Take one heaped tablespoon of the mix and roll it into a ball in the palm of
your hand.
vi) Roll the fat bomb around in the shredded coconut until coated and place on a
tray lined with baking paper.
vii) When all of the mix has been rolled into fat bombs, place the tray in the
refrigerator for 1 hour, or until the balls have firmed up.
viii) When the fat bombs are firm, they're ready to eat. Keep them in the fridge
(particularly if you live in hot climates), they will keep for a week.
3) Buffalo Chicken Sausage Balls
a) Ingredients
i) Sausage Balls:
(1) 2 14- ounce packages al fresco fresh Buffalo-Style chicken
sausage casings removed
(2) 2 cups almond flour
(3) 1 ½ cups shredded cheddar cheese
(4) ½ cup crumbled blue cheese optional
(5) 1 tsp salt
(6) ½ tsp pepper
ii) Blue Cheese Ranch Dipping Sauce:
(1) 1/3 cup mayonnaise
(2) 1/3 cup unsweetened almond milk can substitute regular milk
(3) 2 cloves garlic minced
(4) 1 tsp dried dill
(5) ½ tsp dried parsley
(6) ½ tsp salt
(7) ½ tsp pepper
(8) ¼ cup crumbled blue cheese or more, if desired
b) Instructions
i) Sausage Balls:
(1) Preheat oven to 350F and line two large baking sheets with parchment
paper or tin foil.
(2) In a large bowl, combine sausage, almond flour, cheddar cheese, bleu
cheese, salt and pepper. Mix thoroughly until well combined.
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(3) Roll into 1-inch balls and place about an inch apart on prepared baking
sheets. Bake 25 minutes, until golden brown. Serve warm with dipping
sauce.
ii) Dipping Sauce:
(1) While sausage balls are baking, combine mayonnaise, almond milk, garlic,
dill, parsley, salt, and pepper in a medium bowl. Stir well and then mix in
crumbled blue cheese.
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Appendix E - Dietary Compliance Checklist
You have been randomized to the Ketogenic diet group. For more details on your assigned diet,
please see handout titled “Low Carbohydrate Foods and Foods to Avoid”. This checklist can be
used to ensure compliance with your ketogenic diet, by tracking intake of these items for your
reference when completing your online weekly check-in survey. During the weekly check-in, you
will be asked to indicate if you consumed any of the foods listed here, and provide the food item
and how much of you consumed.
Day

Food Groups
(circle all that apply)

Fruit (fresh, dried, or
frozen)
Starchy vegetables
Beans
Pasta
Monday

Breads (bagels, toast,
buns, English muffins)
Cereal (hot or cold)
Candy, Cookies, Cakes,
Chips
Sports drinks/ Sugary
drinks
Milk/dairy/alternatives
Fruit (fresh, dried, or
frozen)
Starchy vegetables
Beans
Pasta
Breads (bagels, toast,
buns, English muffins)

Tuesday

Cereal (hot or cold)
Candy, Cookies, Cakes,
Chips
Sports drinks/ Sugary
drinks
Alcohol
Milk/dairy/alternatives

Item

Quantity
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Fruit (fresh, dried, or
frozen)
Starchy vegetables
Beans
Pasta
Breads (bagels, toast,
buns, English muffins)
Wednesday

Cereal (hot or cold)
Candy, Cookies, Cakes,
Chips
Sports drinks/ Sugary
drinks
Alcohol
Milk/dairy/alternatives
Fruit (fresh, dried, or
frozen)
Starchy vegetables
Beans
Pasta

Thursday

Breads (bagels, toast,
buns, English muffins)
Cereal (hot or cold)
Candy, Cookies, Cakes,
Chips
Sports drinks/ Sugary
drinks
Alcohol
Milk/dairy/alternatives
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Fruit (fresh, dried, or
frozen)
Starchy vegetables
Beans
Pasta

Friday

Breads (bagels, toast,
buns, English muffins)
Cereal (hot or cold)
Candy, Cookies, Cakes,
Chips
Sports drinks/ Sugary
drinks
Alcohol
Milk/dairy/alternatives
Fruit (fresh, dried, or
frozen)
Starchy vegetables
Beans
Pasta

Saturday

Breads (bagels, toast,
buns, English muffins)
Cereal (hot or cold)
Candy, Cookies, Cakes,
Chips
Sports drinks/ Sugary
drinks
Alcohol
Milk/dairy/alternatives
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Fruit (fresh, dried, or
frozen)
Starchy vegetables
Beans
Pasta

Sunday

Breads (bagels, toast,
buns, English muffins)
Cereal (hot or cold)
Candy, Cookies, Cakes,
Chips
Sports drinks/ Sugary
drinks
Alcohol
Milk/dairy/alternatives
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Appendix F – Urinary Ketone Daily Record
You have been randomized to the Ketogenic diet group. This record is designed to assess your
compliance with your assigned diet by measuring ketones in your urine. You will test your
urine each morning before having anything to eat or drink (except plain water). Drinking
plain water is encouraged to ensure that you are hydrated and can produce the required urinary
sample. You will report these results to your researcher each week along with your Dietary
Compliance Checklist during your online weekly check-in survey.
To test your urinary ketones, follow these steps:

1) Collect a small sample of your urine in one of the provided cups.
2) Place the end of the ketone testing strip in the urine sample and let it to sit for the
specified time listed in the instructions on the testing strips bottle.
3) After this time has passed, remove the testing strip from the urine sample and
compare the color of the testing strip to the provided chart on the testing strips
bottle.
4) Use the matching color to determine whether your sample was a positive or
negative for ketones.
5) Indicate your daily result in the chart – write “+” for a positive test result and “−”
for a negative test result.
Day 1
Week 0
Week 1
Week 2
Week 3
Week 4
Week 5
Week 6
Week 7
Week 8
Week 9
Week 10
Week 11
Week 12
Week 13

Day 2

Day 3

Day 4

Day 5

Day 6

Day 7
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Food Intake Record
Day
Meal
(breakfast,
lunch, dinner,
snack)

Time

1
2
3
Circle one option
Meal Location
(restaurant, home,
work, etc.)

4

Date: ______________

Name of Food Item or
Beverage (provide as
much detail as possible,
one food item per line)

Amount consumed (cups, tsp., Tbsp.,
ounces, etc.)
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DASH Diet Handout
Participant ID #: ________________
Welcome to our research study and thank you for your participation! If you have any questions
or concerns at any time during your participation, please contact our research team.
Graduate Student Researcher
Jordan Murrin
murrinja@dukes.jmu.edu
703-565-3001

Research Supervisor
Jeremy Akers, PhD, RDN
akersjd@jmu.edu
540-568-8974

Appendix A – DASH Diet
Dietary Approaches to Stop Hypertension (DASH) is a balanced eating plan that promotes lifelong heart-healthy dietary patterns. It does not require any specific foods, but instead
recommends: 1) eating a wide variety of vegetables, fruits, and whole grains; 2) moderating
consumption of fat-free or low-fat dairy products, fish, poultry, beans, nuts, and vegetable oils;
and 3) limiting foods that are high in saturated fat, such as fatty meats, full-fat dairy products, and
tropical oils such as coconut, palm kernel, and palm oils.
To benefit from DASH, it is important to eat the appropriate number of calories to achieve and
maintain a healthy weight. You can accomplish this by reading nutrition labels on food, planning
your meals, and even using the provided resources to make heart-healthy recipes.
This handout is meant to provide you with recommendations that you may use to maintain the
DASH diet. The tables on the next page outlines the main food groups and provides the
approximate number of daily servings, different amounts of foods that equal one serving size, and
examples of nutritious foods for each group. By following these recommendations, your diet will
be: lower in saturated and trans fats; higher in potassium, calcium, magnesium, fiber, and protein;
and lower in sodium. Additional tips for lowering your intake of sodium/salt are provided below.
Approximate Daily Calorie Needs for Men

Age (years)

19–30
31–50
51+

Calories Needed
for Sedentary
Activity Level
2,400
2,200
2,000

Approximate Daily Calorie Needs for Women

Calories Needed
for Moderately
Active Activity
Level
2,600–2,800
2,400–2,600
2,200–2,400

Calories Needed
for Active Activity
Level
3,000
2,800–3,000
2,400–2,800
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Age (years)

Calories Needed
for Sedentary
Activity Level

19–30
31–50
51+

1,800-2,000
1,800
1,600

Calories Needed
for Moderately
Active Activity
Level
2,000-2,200
2,000
1,800

Calories Needed
for Active Activity
Level
2,400
2,200
2,200

Ways to Control Calories
The DASH eating plan can be used to help you lose weight. To lose weight, follow the DASH
eating plan and try to reduce your total daily calories gradually. Find out your daily calorie needs
or goals using a Body Weight Planner and calorie chart.
General tips for reducing daily calories include:
• Eat smaller portions more frequently throughout the day.
• Reduce the amount of meat that you eat while increasing the amount of fruits, vegetables,
whole grains, or dry beans.
• Substitute low-calorie foods, such as when snacking (choose fruits or vegetables instead
of sweets and desserts) or drinking (choose water instead of soda or juice), when
possible.
Increasing Daily Potassium
The DASH eating plan is designed to be rich in potassium, with a target of 4,700 mg potassium
daily, to enhance the effects of reducing sodium on blood pressure. The following are examples
of potassium-rich foods.

Food

Potassium (mg)

Food

Potassium (mg)

Potato, 1 small
Plain yogurt, nonfat or
low-fat, 8 ounces
Sweet potato, 1
medium
Orange juice, fresh, 1
cup

738

Prunes, stewed, ½ cup

398

530–570

Skim milk, 1 cup

382

542

Apricots, ¼ cup

378

496

Pinto beans, cooked, ½
cup
Pork tenderloin, 3
ounces

373

Lima beans, ½ cup

478

371

Soybeans, cooked, ½
cup

443

Lentils, cooked, ½ cup

365

Banana, 1 medium

422

Kidney beans, cooked,
½ cup

360

Fish (cod, halibut,
rockfish, trout, tuna),
3 ounces

200–400

Split peas, cooked, ½
cup

360

Tomato sauce, ½ cup

405

Almonds, roasted, ⅓
cup

310
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Tips for Lowering Sodium When Shopping, Cooking, and Eating Out
•

•

•

Shopping
o Choose items that are lower in sodium and salt, particularly frozen or
prepackaged convenience foods and condiments.
o Choose fresh lean meats, poultry, and fish instead of cured food such as bacon
and ham.
o Choose fresh or frozen versus canned fruits and vegetables.
o Avoid food with added salt, such as pickles, pickled vegetables, olives, and
sauerkraut.
o Avoid instant or flavored rice and pasta.
Cooking
o Don’t add salt when cooking rice, pasta, and hot cereals.
o Flavor your foods with salt-free seasoning blends, fresh or dried herbs and spices,
or fresh lemon or lime juice.
o Rinse canned foods or foods soaked in brine to remove the sodium.
o Use less table salt to flavor food.
Eating Out
o Ask that foods be prepared without added salt.
o Avoid choosing menu items that have salty ingredients such as bacon, pickles,
olives, and cheese or that include foods that are pickled, cured, smoked, or made
with soy sauce or broth.
o Choose fruit or vegetables as a side dish, instead of chips or fries.
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Food Groups
Grains

a

Lean meats, poultry,
and fish

Servings
per day
6–8
6 or less

Vegetables

4–5

Fruits

4–5

Low-fat or fat-free
dairy productsc

2–3

Fats and oilsd

2–3

Nuts, seeds, and
legumes (dry beans)
Sweets and added
sugars

4–5
per week
5 per week

Sodiume

£ 2,300 mg

Water

~ 3.7 L
(125 fl oz)

DASH Daily Eating Plan for 2000 Calories
Equivalent Serving Size
1 slice bread
1 cup ready-to-eat cerealb
½ cup cooked rice, pasta, or cerealb
1-ounce cooked lean meat, skinless poultry, or
fish
1 egg
1 cup raw leafy vegetable
½ cup cooked vegetable
6 ounces vegetable juice
1 medium fruit
¼ cup dried fruit
½ cup fresh, frozen, or canned fruit
6 ounces 100% fruit juice
8 ounces 1% or skim milk
1 cup low-fat or nonfat yogurt
1½ ounces part-skim cheese
1 teaspoon soft margarine
1 tablespoon low-fat mayonnaise
2 tablespoons light salad dressing
1 teaspoon vegetable oil
1/3 cup or 1½ ounces nuts
2 tablespoon nut butter
2 tablespoon or ½ ounce seeds
½ cup cooked dry beans
1 tablespoon sugar
1 tablespoon jelly or jam
½ ounce jelly beans
8 ounces lemonade
Low sodium: £ 140 mg*
Very low: £ 35 mg*
Sodium free: £ 5 mg*
---

Examples and Notes

Whole-wheat bread and rolls, whole-wheat pasta,
English muffin, pita bread, bagel, cereals, grits,
oatmeal, brown rice, unsalted pretzels and popcorn
Select only lean; trim away visible fats; broil, roast, or
poach; remove skin from poultry
Broccoli, carrots, collards, green beans, green peas,
kale, lima beans, potatoes, spinach, squash, sweet
potatoes, tomatoes
Apples, apricots, bananas, dates, grapes, oranges,
grapefruit, grapefruit juice, mangoes, melons, peaches,
pineapples, raisins, strawberries, tangerines
Fat-free milk or buttermilk; fat-free, low-fat, or
reduced-fat cheese; fat-free/low-fat regular or frozen
yogurt
Soft margarine, vegetable oil (canola, corn, olive,
safflower), low-fat mayonnaise, light salad dressing
Almonds, filberts, mixed nuts, peanuts, walnuts,
sunflower seeds, peanut butter, kidney beans, lentils,
split peas
Fruit-flavored gelatin, fruit punch, hard candy, jelly,
maple syrup, sorbet and ices, sugar
*mg of sodium per serving

---
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a

Whole grains are recommended for most grain servings as a good source of fiber and nutrients.

b

Serving sizes vary between ½ cup and 1¼ cups, depending on cereal type. Check the product's
Nutrition Facts label.
c

For lactose intolerance, try either lactase enzyme pills with dairy products or lactose-free or
lactose-reduced milk.
d

Fat content changes the serving amount for fats and oils. For example, 1 Tbsp regular salad
dressing = one serving; 1 Tbsp low-fat dressing = one-half serving; 1 Tbsp fat-free dressing =
zero servings.
e

The DASH eating plan has a sodium limit of either 2,300 mg or 1,500 mg per day. 1,500 mg of
daily sodium lowers blood pressure more than 2,300 mg daily sodium.

Adapted from the National Heart, Lung, and Blood Institute
(http:/www.nhlbi.nih.gov/health/health-topic
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Appendix B – Sample Menus
Sample Menu 1
Breakfast (376 kcal, 70 g carbs, 6 g fat, 16 g protein, 421 mg sodium, 33 g sugar)
- ½ cup whole grain cereal with raisins, low-fat
- 1 cup 1% milk
- 1 slice 100% whole wheat toast
- 1 tbsp jelly/jam
Snack (285 kcal, 34 g carbs, 6 g fat, 26 g protein, 285 mg sodium, 9 g sugar)
- 1 cup plain nonfat Greek yogurt
- ¼ cup grain cereal/oats (on top of yogurt)
Lunch (558 kcal, 97 g carbs, 9 g fat, 26 g protein,
- 3 oz Oven-roasted Chicken Breast
- 1 cup Brown Rice
- 1 cup Mixed Vegetables
- 1 medium fruit

495 mg sodium, 22 g sugar)

Snack (427 kcal, 32 g carbs, 27 g fat, 13 g protein, 107 sodium, 24 g sugar)
- 1/2 cup trail mix (nuts, dried fruit, seeds, dark chocolate chips)
Dinner (487 kcal, 67 g carbs, 11 g fat, 33 g protein, 904 sodium, 12 g sugar)
- 3 oz Flank Steak
- 2/3 cup Rice Pilaf
- ½ cup baked sweet potato fries
- 1 cup steamed collard greens
- ½ cup grapes
Totals: 2133 kcal, 114 g protein, 300 g carbs (100 g sugar), 59 g fat, 2200 mg sodium
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Sample Menu 2
Breakfast (518 kcal, 74 g carbs, 9 g fat, 41 g pro,
- 1 eggs, scrambled
- 1 slice 100% whole wheat toast
- 1 cup plain nonfat Greek yogurt
- ¼ cup grain cereal/oats (on top of yogurt)
- 1 cup mixed berries

528 mg sodium, 25 g sugar)

Snack (188 kcal, 14 g carbs, 14 g fat, 7 g protein, 0 mg sodium, 7 g sugar)
- 3 tbsp whole almonds
- ½ cup fresh fruit
Lunch (534 kcal, 88 g carbs, 5 g fat, 19 g protein,
- 3 oz teriyaki (low sodium) salmon
- 1 cup stir-fried vegetables
- 1 cup Brown Rice
- 1 medium fruit

548 mg sodium, 20 g sugar)

Snack (200 kcal, 20 g carbs, 10 g fat, 10 g protein, 370 mg sodium, 1 g sugar)
- 1 oz nonfat or light butter popcorn
- 1 part-skim cheese stick or 1 oz low fat cheese
Dinner (514 kcal, 51 g carbs, 21 g fat, 26 g protein, 531 mg sodium, 20 g sugar)
- 3 oz baked pork loin
- 2 oz square cornbread
- ½ cup natural low sodium applesauce
- 1 cup steamed baby carrots
Totals: 1,954 kcal, 247 g carbs, 59 g fat, 103 g protein, 1,977 mg sodium, 73 g sugar
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Appendix C - Meal Planning Resources
Recipe Resources

1. https://healthyeating.nhlbi.nih.gov/default.aspx
2. https://healthyeating.nhlbi.nih.gov/pdfs/Dinners_Cookbook_508-compliant.pdf
3. https://www.mayoclinic.org/healthy-lifestyle/recipes/dash-diet-recipes/rcs20077146
4. https://www.foodnetwork.com/healthyeats/recipes ‘
5. https://www.tasteofhome.com/collection/dash-diet-recipes/view-all/
6. http://thedashdiet.net/
Sample Recipes
1) Cinnamon-glazed Baby Carrots
a) 4 cups baby carrots, rinsed and split lengthwise if very thick (or frozen pre-sliced
carrots); 2 tbsp soft tub margarine; 2 tbsp brown sugar; ½ tsp ground cinnamon; 1/8 tsp
salt
b) Directions
i) Place the carrots in a small saucepan. Add just enough water to barely cover the
carrots. Cover. Bring to a boil. Reduce heat to medium. Cook for 7–8 minutes, just
until the carrots are easily pierced with a sharp knife.
ii) While the carrots are cooking, combine margarine, brown sugar, cinnamon, and salt
in a small saucepan, and melt together over low heat (or put in a microwave-safe
bowl and microwave for a few seconds on high power, until margarine is mostly
melted). Stir well to combine ingredients.
iii) Drain carrots, leaving them in the saucepan. Pour cinnamon mixture over carrots.
Cook and stir over medium heat for 2–3 minutes, just until the carrots are thoroughly
coated and the glaze thickens slightly. Serve warm.
2) Good-for-you Cornbread
a) 1 cup cornmeal; 1 cup flour; ¼ cup sugar; 1 tsp baking powder; 1 cup low-fat (1%)
buttermilk; 1 large egg; ¼ cup soft tub margarine; 1 tsp vegetable oil (to grease baking
pan)
b) Directions
i) Preheat oven to 350 °F.
ii) Mix together cornmeal, our, sugar, and baking powder.
iii) In another bowl, combine buttermilk and egg. Beat lightly. Slowly add buttermilk
and egg mixture to dry ingredients. Add margarine and mix for 1 minute.
iv) Bake for 20–25 minutes in an 8- by 8-inch, greased baking dish. Cool. Cut into 10
squares.
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3) Greek Style Flank Steak with tangy yogurt sauce
a) 1 beef flank steak (12 oz)
b) For marinade: ¼ cup lemon juice; 1 tbsp olive oil; 2 tsp fresh oregano, rinsed dried and
chopped (or ½ tsp dried); 1 tbsp garlic, minced (about 2-3 cloves)
c) For yogurt sauce: 1 cup cucumber, peeled, seeded, and chopped; 1 cup nonfat plain
yogurt; 2 tbsp lemon juice; 1 tbsp fresh dill rinsed dried and chopped (or ½ tsp dried); 1
tbsp garlic, minced (about 2-3 cloves); ½ tsp salt
d) Directions
i) For the marinade, combine lemon juice, olive oil, oregano, and garlic in a large bowl.
ii) Lay steak in a container with sides and pour marinade over the steak. Let the steak
marinate for at least 20 minutes or up to 24 hours, turning several times.
iii) Combine all the ingredients for the yogurt sauce. Set yogurt sauce aside for at least
15 minutes to blend flavors. (Sauce can be prepared up to 1 hour in advance and
refrigerated.)
iv) Preheat oven broiler on high temperature, with the rack 3 inches from heat source.
v) Broil steak for about 10 minutes on each side (to a minimum internal temperature of
145 F). Let cool for 5 minutes before carving.
vi) Slice thinly across the grain into 12 slices (1 ounce each).*
vii) Serve three slices of the steak with 1⁄2 cup yogurt sauce on the side.
4) Grilled Tuna with Chickpea and Spinach salad
a) 1 Tbsp olive or canola oil; 1 Tbsp garlic, minced (about 2–3 cloves); 2 Tbsp lemon juice;
1 Tbsp oregano, minced (or 1 tsp dried); 12 oz tuna steaks, cut into 4 portions (3 oz each)
b) For salad: ½ can (15½ oz) low-sodium chickpeas (or garbanzo beans), drained and
rinsed; ½ bag (10 oz) leaf spinach, rinsed and dried; 1 Tbsp lemon juice; 1 medium
tomato, rinsed and cut into wedges; 1/8 tsp salt; 1/8 tsp ground black pepper
c) Directions
i) Preheat grill pan or oven broiler (with the rack 3 inches from heat source) on high
temperature.
ii) Combine oil, garlic, lemon juice, and oregano, and brush over tuna steaks. Marinate
for 5–10 minutes.
iii) Meanwhile, combine all salad ingredients. (Salad can be made up to 2 hours in
advance and refrigerated.)
iv) Grill or broil tuna on high heat for 3–4 minutes on each side until the flesh is opaque
and separates easily with a fork (to a minimum internal temperature of 145 °F).
v) Serve one tuna steak over 1 cup of mixed salad.
5) Mixed Veggies # 1
a) Asparagus; bell peppers; mushrooms
b) Roasted or sautéed with olive or vegetable oil
6) Mixed Veggies # 2
a) Zucchini/squash; carrots; green beans
b) Steamed
7) Oven-crusted Chicken Breast
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a) For Chicken: 4 boneless, skinless chicken breasts (3 oz each); 1 egg white; 1 cup fat-free
evaporated milk; 1 cup breadcrumbs; ¼ cup rolled oats, crushed (pulse a few times in the
food processor or crush between fingers to make smaller pieces); 1 cup whole-wheat
flour; 2 tbsp olive oil or vegetable oil
b) For Salad: 2 tbsp lemon juice; ½ tbsp. olive oil; 4 cups red leaf lettuce, rinsed and dried;
1 cup cherry tomatoes, rinsed and halved; ¼ tsp salt; ¼ tsp ground black pepper
c) Directions
i) Preheat oven to 350 °F.
ii) Place chicken in a freezer bag with the air squeezed out, and pound each breast down
to 1⁄2-inch thickness.
iii) Combine the egg white and evaporated milk in a bowl and mix well. In a separate
bowl, combine the breadcrumbs and crushed oats, and mix well.
iv) Coat the chicken breasts in flour and shake off the excess. Dip the chicken breasts in
the egg and milk mixture and drain off the excess. Then dip the chicken breasts in the
breadcrumb mixture to coat and shake off the excess. After all chicken breasts have
been coated, discard any leftover breading mixture.
v) Heat oil in a large sauté pan. Stir fry the chicken over medium-high heat on one side
until golden brown, about 2–3 minutes. Turn carefully, and pan fry the second side
for an additional 2–3 minutes or until golden brown. Remove from the pan, and place
on paper towels to soak up excess oil. Place on baking sheet, and finish cooking in a
350°F oven for about 5–8 minutes (to a minimum internal temperature of 165°F).
vi) For the salad, combine lemon juice and olive oil, and mix well to make a dressing.
Toss the lettuce leaves and cherry tomatoes with the dressing, salt, and pepper.
vii) Serve 1 cup salad with one piece of chicken.
8) Parmesan Rice and Pasta Pilaf
a) 2 tbsp olive oil; ½ cup thin spaghetti, finely broken, uncooked; 2 tbsp onion, diced; 1 cup
long-grain white rice, uncooked; 1¼ cups chicken broth, hot; 1¼ cups water, hot; ¼ tsp
ground white pepper; 1 bay leaf; 2 tbsp shredded parmesan cheese
b) Directions
i) In a large sauté pan, heat the oil. Sauté vermicelli and onion until golden brown (for
about 2–4 minutes) over medium-high heat. Drain off oil.
ii) Add rice, chicken broth, water, pepper, and bay leaf. Cover and simmer for 15–20
minutes. Fluff with fork. Cover and let stand for 5 minutes. Remove bay leaf.
iii) Sprinkle with shredded parmesan cheese and serve immediately.
9) Pork Mignons with French Applesauce
a) 1 pair pork tenderloins (about 2 lbs.); 1⁄4 tsp salt; 1/8 tsp ground black pepper;
2
medium apples, rinsed and cored, but not peeled (try Golden Delicious or Rome); 2 tbsp
dark seedless raisins; 2 tbsp walnut, broken into coarse pieces;
½ tsp cinnamon;
Cooking spray
b) Directions
i) Preheat oven broiler on high temperature, with the rack 3 inches from heat source.
ii) Cover broiler pan with aluminum foil for easy cleanup. Spray foil lightly with
cooking spray. Set aside.
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iii) Cut 8 slices (pork rounds), each 11⁄2 inches thick, from the center of the pair of pork
tenderloins. Refrigerate or freeze the ends for another use. Place pork rounds on the
foil-covered broiler pan. Sprinkle with salt and pepper. Set aside a few minutes while
broiler heats.
iv) Meanwhile, heat 1⁄2 cup water to boiling in a medium nonstick pan. Slice cored
apples from top to bottom in 1⁄4-inch wide pieces. Add apples, raisins, walnuts, and
cinnamon to boiling water. Reduce heat to medium. Cover. Simmer, stirring
occasionally, until apples are soft and easily pierced with a fork. Set aside until pork
is cooked.
v) Broil pork for 5–10 minutes per side (to a minimum internal temperature of 160 °F).
vi) To serve, place two pork rounds on each dinner plate. Top with ¼ of the applesauce.
10) Savory Brown Rice
a) 1 tbsp olive oil; 1 cup onion, chopped; 1 cup portabella mushrooms, rinsed, halved, thinly
sliced; ½ cup celery, rinsed and finely diced; 2 cups low-sodium chicken broth; 1 cup
instant brown rice, uncooked; ¼ cup dried parsley; ¼ tsp salt; Add black pepper to taste
b) Directions
i) In a 4-quart saucepan, warm olive oil over medium heat. Add onion, mushrooms, and
celery. Cook and stir for 5–7 minutes, until all vegetables are soft, but not brown.
ii) Stir in the chicken broth, brown rice, parsley, salt, and pepper. Cover. Bring to a boil
over high heat.
iii) Reduce heat to medium. Cook according to brown rice package directions, about 5–
10 minutes. Drain off any excess liquid. Fluff with a fork. Serve immediately.
11) Teriyaki-glazed salmon with stir-fried vegetables
a) For Salmon: 2 tbsp light teriyaki sauce; ¼ cup mirin (or sweet rice wine); 2 tbsp rice
vinegar; 2 tbsp scallions (green onions), rinsed and minced; 1½ tbsp. ginger, minced (or 1
tsp ground); 12 oz salmon fillets, cut into 4 portions (3 oz each)
b) For Vegetables: 1 bag (12 oz) frozen vegetable stir-fry; ½ tbsp peanut oil or vegetable oil;
½ tbsp. garlic, minced (about 1 clove); 1 tbsp ginger, minced (or 1 tsp ground); 1 tbsp
scallions (green onions), rinsed and minced; 1 tbsp lite soy sauce
c) Directions
i) Thaw frozen vegetables in the microwave (or place entire bag in a bowl of hot
water for about 10 minutes). Set aside until step 7.
ii) Preheat oven to 350 F.
iii) Combine teriyaki sauce, mirin, rice vinegar, scallions, and ginger. Mix well. Pour
over salmon and marinate for 10–15 minutes.
iv) Remove salmon from the marinade and discard unused portion.
v) Place salmon on a baking sheet and bake for 10–15 minutes or until fish flakes easily
with a fork in the thickest part (to a minimum internal temperature of 145 °F).
vi) Meanwhile, heat oil in a large wok or sauté pan. Add garlic, ginger, and scallions,
and cook gently but do not brown, about 30 seconds to 1 minute.
vii) Add vegetables, and continue to stir fry for 2–3 minutes or until heated through.
Add soy sauce.
viii)
Serve one piece of salmon with 1 cup of vegetables.
d) Tip: Try serving with steamed rice or Asian-style noodles (soba or udon).
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Food Intake Record
Day
Meal (breakfast,
lunch, dinner,
snack)

1
2
3
Circle one option
Time

4

Meal Location
(restaurant, home,
work, etc.)

Date: ______________
Name of Food Item or Beverage (provide
as much detail as possible, one food item
per line)

Amount consumed
(cups, tsp., Tbsp.,
ounces, etc.)
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